The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

12-2020

INDUCIBLE EPITHELIAL RESISTANCE AGAINST ACUTE VIRAL
PNEUMONIA AND CHRONIC ASTHMA
Shradha Wali

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Immunology and Infectious Disease Commons

Recommended Citation
Wali, Shradha, "INDUCIBLE EPITHELIAL RESISTANCE AGAINST ACUTE VIRAL PNEUMONIA AND
CHRONIC ASTHMA" (2020). The University of Texas MD Anderson Cancer Center UTHealth Graduate
School of Biomedical Sciences Dissertations and Theses (Open Access). 1042.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1042

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

INDUCIBLE EPITHELIAL RESISTANCE AGAINST ACUTE VIRAL PNEUMONIA
AND CHRONIC ASTHMA
By Shradha Wali, M.S.
APPROVED:
__________________________
Scott E. Evans, M.D., Advisory Professor
__________________________
Kimberly Schluns, Ph.D.
__________________________
Seyed Moghaddam, M.D.
__________________________
Joya Chandra, Ph.D.
__________________________
Jeffrey Actor, Ph.D.
__________________________
Rick Wetsel, Ph.D.

APPROVED:
__________________________
Dean, The University of Texas
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences

i

INDUCIBLE EPITHELIAL RESISTANCE AGAINST ACUTE VIRAL PNEUMONIA
AND CHRONIC ASTHMA
A
DISSERTATION

Presented to the Faculty of
The University of Texas
MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences
in Partial Fulfilment
of the Requirements
for the Degree of
DOCTOR OF PHILOSOPHY
by
Shradha Wali, M.S.
December 2020

ii

Copyright
mBIO, British Journal of Pharmacology (BJP), and American Thoracic Society (ATS)
permit authors to reuse their articles or parts of their articles in several ways
including in support of his/her thesis or dissertation.
The full list of copyrights and permissions granted to authors who publish in mBIO,
BJP and ATS can be found at the following web address:
Copyright © 2019 Kirkpatrick et al https://journals.asm.org/content/permissions
https://bpspubs.onlinelibrary.wiley.com/hub/journal/14765381/permissions.html
Copyright © 2020 British Journal of Pharmacology
https://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=97fcf6ae-454f-492e-a5a7bfec333d5889
Reprinted with permission of the American Thoracic Society.
Copyright © 2020 American Thoracic Society. All rights reserved.
The American Journal of Respiratory Cell and Molecular Biology is an official journal
of the American Thoracic Society.
(https://www.atsjournals.org/doi/10.1165/rcmb.2020-0241OC)

iii

Acknowledgments
I would sincerely like to thank my PhD advisor and mentor Dr. Scott E. Evans
for his endless support, guidance, patience, and dedication to my scientific training
as a PhD student. I cannot possibly thank you enough for your patient approach to
everything during my graduate studies. Thank you for always going the extra mile in
supporting me in all my scientific endeavors especially taking the time out to train me
to communicate my science effectively. Thank you for the numerous opportunities
you supported and guided me to become a good communicator and presenter of
science. You have taught me a lot beyond science. Your patient demeanor towards
listening to my scientific and non-scientific problems will go a long way in my
mentorship approach towards my future trainees. I hope in my future when I train
graduate students and postdocs, I can create the same comfortable space you
created for me for all kinds of conversations in science and beyond. I am truly
grateful for the wonderful lab atmosphere you have established.
To my advisory committee, Drs. Kimberly Schluns, Joya Chandra, Seyed
Moghaddam, Rick Wetsel, and Jeffrey Actor, thank you for your incredible support,
guidance, wisdom in my project all these years. You have shaped me to be a
dedicated scientist, become a good communicator and presenter of science, and
supported all my scientific endeavors. Thank you for your unbiased opinions and
career advice and constant support in everything I pursue. In a similar vein, I would
like to thank Dr. Burton Dickey for all his help and tremendous input in my research.
Thank you also for helping me present and write scientific data in an efficient
manner. To Deans Shelley Barton and Michael Blackburn, I am honored that you
iv

supported me serving on the GSBS Curriculum Committee as a student
representative. It was a great opportunity for me to shape the incoming graduate
students' experience by continually reviewing and honing the curriculum. It was also
amazing to see the dedication of GSBS faculty and staff to support the student
community.
To all the Evans lab members and Pulmonary Medicine Department members,
thank you for your support, guidance, friendship, companionship all these years. Dr.
Miguel Leiva, thank you for patiently teaching me several valuable research
techniques in the lab that I am now facile in. Dr. Jezreel Pantaleon Gracia, thank you
for all the endless discussions we have had, about science and beyond and the
countless laughs we have shared. Dr. Jose Flores and David Goldblatt, it has been
great working with you both on the chronic asthma studies, and thanks for all your
help in my research. Your input and countless discussions and reviewing of the data
were especially very helpful. Jose, I cannot forget the fun I had with you and Adriene
while we were at our first ATS conference in D.C. Those moments will always be
remembered and cherished. Thank you for all the times you have helped me
harvesting mouse lung samples in the animal room. David, the countless
discussions on research design and science, in general, we have had will truly
remain one of my best memories during my PhD. Dr. Yongxing Wang, thank you for
sharing your expertise in genetics and mouse models, it has been a great help.
Vikram Kulkarni, thank you for always offering your helping hand and all your
contribution towards my thesis. Thank you, Dr. Jichao Chen, Danielle, and

v

Lissandra, for teaching me several important microscopic and immunofluorescence
techniques, which I will continue to use in my future research.
To my family and friends, from GSBS and beyond, thank you for your endless
support throughout my experience as a graduate student. My best friends,
Aishwarya, Dani, and Bhargavi, words cannot express how grateful I am for your
support and motivation. Thank you for the numerous laughs we have had and for
giving me a shoulder to cry on when times were tough. Thank you for the various
skype sessions and always adjusting your time schedules for my benefit. Farah, Ana
Maria, Danielle, Lissandra, and Odemaris, thank you for always being there by my
side. Danielle, thank you for all your scientific editing support and input. I have had
one of my best scientific experiences as a student editor discussing science outside
of my horizon and in the process of becoming a better and more evolved scientist.
Odemaris, thank you for the words of wisdom and hugs (during the pre-COVID
pandemic era) we shared in the hallways which lifted my spirits now and then.
Farah, thanks for being there from day one of our GSBS journeys and providing
tremendous support all these years. We have both grown and learned a lot during
our graduate school experience and I will always cherish all our memories together.
Thank you to my sisters Nayana and Sneha, who never failed to be by my side
since my undergraduate studies when I announced I would be pursuing a scientific
research career path, something that was unheard of in our family of non-scientists.
Thank you to my mother Meenaxi, for all your motivation, support, and sacrifice all
these years without any of which I would not be the person or a scientist I am today.
You guys are always so excited and happy when I shared any small
vi

accomplishments during my graduate school, be it an award, or publication of my
research articles. It is truly not possible for me to pen down your contributions to my
career. I am so fortunate to have you guys by my side throughout my life.
Lastly, I want to extend my gratitude towards my master’s thesis mentors Drs.
Bernard Arulanandam, Rishein Gupta, and JiehJuen Yu for their support in my prePhD training. The research experience I gained under your tutelage has been eyeopening in many ways and has laid a strong foundation not only for my PhD but will
help shape my future research as well. Thank you for having faith in me to carry out
high-end projects and for always supporting me towards my PhD training.

vii

Abstract
Inducible epithelial resistance against acute viral pneumonia and chronic
asthma
By Shradha Wali, M.S.
Advisory Professor: Scott E. Evans, M.D.
Viral pneumonia remains a global health threat despite worldwide vaccination
and therapeutic programs. The influenza pandemic of 1918 and SARS-CoV2
pandemic of 2019-2020 are cautionary reminders demanding the need for novel
treatment strategies. Moreover, in addition to causing acute disease, respiratory
virus infections are often complicated by chronic lung pathologies, such as asthma
induction, progression, and exacerbation. We have reported that mice treated with a
combination of inhaled Toll-like receptor (TLR) 2/6 and TLR 9 agonists (Pam2-ODN)
to stimulate innate immunity are broadly protected against respiratory pathogens,
but the mechanisms underlying this protection remain incompletely elucidated. Here,
we show in a lethal paramyxovirus model that Pam2-ODN-enhanced survival is
associated with robust virus inactivation by reactive oxygen species (ROS), which
occurs prior to internalization by lung epithelial cells. We also found that mortality in
sham-treated mice temporally corresponded with CD8+ T cell-enriched lung
inflammation that peaks on days 11-12 after viral challenge, when the viral burden
has waned to a scarcely detectable level. Pam2-ODN treatment blocked this
injurious inflammation by reducing the viral burden. Alternatively, depleting CD8+ T
cells 8 days after viral challenge also decreased mortality. Notably, Pam2-ODN
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treatment of mice lacking CD8+ T cells at any point of SeV infection showed a similar
degree of protection demonstrating Pam2-ODN mediated protection independent of
CD8+ T cell response. Further, Pam2-ODN treatment protected SeV challenged
mice from progressing to asthma-like disease by initiating acute anti-viral effects.
Interestingly, mice aerosolized with Pam2-ODN after viral clearance displayed
reduced eosinophilia that was associated with reduced lung epithelial IL-33
production. Findings from this study reveal opportunities for targeted
immunomodulation to protect susceptible individuals from mortality of respiratory
virus infections and preventing progression to chronic asthma.
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Chapter I: Introduction
1.1 Global burden of respiratory viral infections
Viral pneumonias remain a global health threat with seasonal influenza and
emerging pandemic viruses such as SARS-CoV-2 inflicting morbidity and mortality in
vulnerable subjects [1-3]. In addition to causing acute disease, respiratory virus
infections are often complicated by chronic lung pathologies such as asthma
initiation, progression, and exacerbation [4-8]. Therefore, novel therapeutic anti-viral
strategies need to be developed to effectively prevent and treat respiratory virus
infections and their associated chronic lung diseases.
Nearly 80% of asthma exacerbations are associated with respiratory viral
infections [4-6, 8] but the mechanisms that link asthma exacerbations and virus
infections remain incompletely understood. In this regard, Michael Holtzman’s group
found that in mice, infection with Sendai virus (SeV), a parainfluenza virus, causes
long-term effects after viral clearance based on a “hit and run” strategy [6, 8-10].
Specifically, initial SeV infection (with viral replication peaking at 5 days and
clearance from lungs by 14 days) is linked to changes in expression of epithelial
immune response genes, inflammation, and subsequent acute hyperreactivity [8,
10]. Additionally, this transient SeV infection triggers potentially lifelong asthma-like
disease characterized by goblet cell metaplasia, eosinophils, and airway
hyperreactivity [6, 8, 9].
Therefore, controlling viral infections and associated disease severity could be
an appealing approach to prevent virus-induced asthma-like disease and
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exacerbations. However, none of the current strategies to treat asthma, such as
corticosteroids and β2-adrenoceptor agonists, target virus-induced asthma
exacerbations [11-13]. Additionally, despite multiple global vaccination programs to
improve public health, these respiratory illnesses continue to significantly increase
health care burden across the world [14-18]. Therefore, to inform future therapeutics
for effective anti-viral programs, we must first note the challenges currently faced in
designing anti-viral vaccination strategies.

1.2 Current challenges in anti-viral vaccine design
Currently licensed influenza vaccines focus on antibody generation specific to
viral membrane proteins that mediate viral entry into host cells [17, 19]. However,
due to antigenic drift resulting in mutated viral membrane proteins, strain-specific
antibody generation is required, necessitating evaluations and reformulations 6-8
months a year to keep pace with antigenic drifts [17, 19]. Further, since systemic
immunity is poor in the elderly population, current vaccines tend to be less
efficacious in this group. This can be countered by using adjuvants or increasing the
antigen dose, however, vaccine studies or systems biology approaches to improve
immunogenicity in the elderly are lacking [16, 17]. Further, when animal-origin
viruses acquire the ability to infect humans resulting in an antigenic shift, there
ensues a lack of immunity against the novel virus [15, 17, 20]. The inability to predict
the virus strains or subtypes that will result in future pandemics and the consequent
delay in vaccine generation has generated great interest in a “universal influenza
vaccine” that can produce broad, cross-reactive immunity, reducing the need for
2

annual vaccine evaluations [16, 20]. In this regard, recent advances have been
made to understand how host innate immune cells can be induced to generate longlasting and heterologous immunity, which will be discussed in the next section.

1.3 Trained innate immunity

For a long time, innate immunity was known to be non-specific and lacking
memory, in contrast to adaptive immunity which is highly specific and long-lasting.
However, invertebrate animals that lack adaptive immunity, display a prolonged
functional state of their innate immunity after sufficient priming. Over the last few
years, Mihai Netea’s group has studied a similar phenomenon in detail, terming it
‘trained innate immunity’. Studies on trained immunity using BCG, polio vaccine, and
measles virus, among other immune stimuli, have shown generation of long-term
protection against bacterial and viral challenges through epigenetic, metabolic, and
functional changes in innate immune cells [21-23]. Perhaps an important functional
change is the induction of memory in innate immune cells such as macrophages,
monocytes, and NK cells that protect against secondary infections [21, 24, 25]. This
protection is shown to persist even in the absence of adaptive immune
compartments [21]. Training of macrophages and monocytes with BCG and βGlucan causes metabolic shifts in these cells from oxidative phosphorylation to
aerobic glycolysis that allow a faster supply of energy and metabolites after a
secondary challenge. Further, trained macrophages undergo epigenetic changes
that result in quick access to transcription factors, controlling the production of
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proinflammatory genes, upon secondary infections [23, 26]. Therefore, epigenetic
priming may be an important mechanism explaining the underlying characteristics of
protective immune memory. One such epigenetic priming mechanism is the
activation of gene transcription upon initial stimuli, which may be accompanied by
specific chromatin marks acquisition such as H3K4me1, H3K4me2, H3K4me3 in
macrophages [22, 27]. These chromatin marks appear to persist at least partially
when the stimulus is removed [27]. This enhanced epigenetic status in the innate
immune cells tagged by the chromatin marks such as H3K4me1 results in a robust
response upon a secondary stimulus or challenge [27].

NK cells have shown both trained innate memory characteristics and classical
immunological memory that is mediated by T and B cells [22, 28]. Studies in mice
showed hapten-induced contact hypersensitivity was dependent on NK cells that
were shown to be persisting for at least 4 weeks [29]. Additional studies using
murine cytomegalovirus (MCMV) infection in mice showed evidence of
immunological memory independent of T and B cells [29, 30]. This memory was
mediated by NK cells that upon reinfection, produce IFN-γ and perforins, thus
inducing a protective response [30, 31]. This NK cell memory is at least partially
driven by epigenetic changes. One study with human CMV showed epigenetic
priming of the IFNG gene locus in NK cells, which acquires specific chromatin marks
[28, 29]. Upon reinfection, these NK cells then show greater IFN-γ generation thus
leading to protective immune response [28, 29].
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While modulation of trained immunity is generally shown to induce broad and
long-term memory in animal studies, functional changes must be induced in the
hematopoietic stem and precursor cells as these cells give rise to multiple
generations of memory-consisting innate immune cells [21-24, 27]. Given the
difficulties of effective vaccine design, the modulation of trained immunity can offer
promising new treatments in the context of emerging new respiratory viruses such
as SARS-CoV2.
This thesis project is focused on understanding how pharmacologic stimulation
of the lung mucosal defenses can attenuate acute viral pneumonia and chronic
asthma. Therefore, it is important to understand the lungs’ mucosal immune
response to viruses and anti-viral defense mechanisms, providing insights into the
design of future therapeutics.

1.4 Pathogenesis of respiratory virus infections
This thesis project is mostly focusing on the mouse model of parainfluenza
virus, Sendai (SeV) infection, but I also use influenza virus (H3N2 strain) in some
experiments. Both influenza and parainfluenza infections are common infections
found in children and adults leading to significant morbidity and mortality. To date,
SeV infection in mice appears to resemble the response to human pathogens such
as influenza, parainfluenza, and RSV and human type 2 immune response seen in
asthma [8]. Since RSV replication in mice is difficult, the SeV mouse model offers an
alternative model to study virus-induced pathogenesis that appears to resemble
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human disease. I will briefly explain the pathogenesis of respiratory virus infection in
this section. Influenza, SeV, or SARS-CoV-2 target the lung epithelium for infection
by binding to the viral receptors on the lung epithelial cells [32-34]. The presence of
viral RNA in the cells leads to the activation of intracellular signaling pathways,
initiating an acute innate immune response via TLR signaling, RIG-I activation, or
inflammasomes [35]. These pathways culminate in the activation of IRF3 or 7, which
activates IFN-α/β transcription for viral clearance [35-37]. Activation of type I IFNs
also leads to proinflammatory cytokine and chemokine production via NF-κB
activation [35, 36]. Further, viral RNA in the cytoplasm can induce a conformational
change in RIG-I that interacts with MAVS protein, which in turn activates IRF3 and
NK-κB to produce type I IFNs and proinflammatory cytokines, respectively [38]. In
addition, inflammasome proteins are induced via NF-κB activation [38]. In the
presence of viral RNA, the NLRP3 inflammasome pathway gets activated which
cleaves and activates caspase-1 producing IL-1β and IL-18, thereby augmenting the
inflammation cascade [38]. Further, infection of lung epithelial cells leads to increase
in damage-associated molecular patterns (DAMPs) that are recognized by dendritic
cells, that migrating to the draining lymph nodes to activate cytotoxic CD8+ T cells
and CD4+ T helper cells and memory CD8+ T cells [38]. The chemokines and
cytokines produced by NK-κB activation lead to the recruitment of neutrophils and
differentiation of monocytes from peripheral blood to monocyte-derived alveolar
macrophages [38]. Both neutrophils and macrophages amplify the inflammation
during the on-going viral infection.
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In the case of the novel SARS-CoV2 infection in humans, the virus uses the
ACE-2 receptor on the lung epithelium for viral entry [32]. Upon transmission,
symptoms appear to be minimal, with viral shedding restricted to the upper
respiratory tract [32, 39]. However, the second week onward, viral replication in the
lower respiratory tract and secondary viremia is seen with an attack on other organs
and cells that express the ACE-2 receptor such as the kidney, heart, and
gastrointestinal tract [32, 39]. This process of viral shedding correlates with clinical
deterioration following disease onset in the second week. It appears that disease
exacerbation in the late stage is not only due to direct viral damage but also a result
of immune-mediated lung injury [39]. The progression to COVID-19 severe disease
in humans is associated with reduced lymphocyte counts and increase neutrophils in
the blood [32, 39]. This is also correlated with increased IL-6, MCP-1, MIP1A, and
TNF-α in the blood plasma [32, 39]. Reduced lymphocyte counts and inflammatory
cytokines appear to be associated with mortality of COVID-19 patients [32, 39].
However, the data regarding immune response and pathogenesis of SARS-CoV2
are evolving and several reports indicate different patterns of clinical manifestations
depending on age, underlying health, and environmental conditions associated with
severe disease induced by SARS-CoV2.

1.5 Host immune response to respiratory virus infections
Alveolar Macrophages: Residing within the alveoli airspaces are
macrophages ideally located to respond to infectious agents in the respiratory tract.
Phenotypically, alveolar macrophages are classified as classically activated (M1)
7

pro-inflammatory type producing high levels of TNF-α, IL-1β, and iNOS in response
to virus infections, and alternately activated (M2) anti-inflammatory type,
predominantly involved in tissue repair and maintaining homeostasis by TGF-β
production [40]. Under homeostatic conditions, macrophage interactions with
epithelial cells help to keep the alveolar macrophages in a suppressive, antiinflammatory state [41, 42]. However, virus infection of epithelial cells and the
subsequent death of infected epithelium leads to enhanced phagocytic activity in
macrophages [41]. In addition to phagocytosis, macrophages release proinflammatory cytokines and chemokines such as CCL5, TNF-α, MCP-1, and IL-6,
which in turn leads to additional immune cell recruitment to the lungs, ultimately
resulting in viral clearance [41-43]. Macrophages can also act as a sink by
absorbing the virus and preventing its spread to nearby cells [44]. The precise role of
alveolar macrophages in viral infections is shown in depletion studies using
clodronate-loaded liposomes that selectively induce macrophage death [42, 45].
Other studies have made use of GM-CSF-/- mice or administration of diphtheria toxin
to CD169-diphtheria toxin receptor mice to study macrophage function in viral
infections [41, 46, 47]. Mice depleted of macrophages by any of these methods have
shown similar results with increased viral burden, enhanced inflammation, and
disease severity, implicating their role in controlling viral infections [40, 43]. Overall,
numerous studies have shown alveolar macrophages to be necessary and
protective in function against viral infections.
Neutrophils: Another group of innate immune cells that respond quickly to an
infection or injury are neutrophils. They arrive from the blood circulation to the lungs
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by the action of proinflammatory cytokines such as IL-1β, IL-6, and TNF-α and
chemokines such as CXCL1, CXCL2, and CXCL8 [48]. Neutrophils actively
phagocytose virus particles and other dead cells containing virus particles [49]. Upon
phagocytosis, neutrophils use a variety of enzymes, ROS, and anti-microbial
peptides to kill pathogens [48, 49]. Another mechanism used by neutrophils is the
release of neutrophil extracellular traps (NETs), after undergoing a form of
programmed cell death. These NETs consist of proteases, chromatin, histones, and
other anti-microbial peptides that inactivate virus particles, hence preventing the
dissemination of viruses [48]. Several studies have shown that the recruitment of
neutrophils and their activities are essential for controlling respiratory virus infections
[48, 49]. However, there are also reports indicating excessive activity of neutrophils
releasing ROS, enzymes, and myeloperoxidase that can injure lung epithelium
during viral infections, leading to uncontrolled inflammation and host damage [50]. In
addition to performing phagocytosis, neutrophils secrete chemokines and cytokines
that can in turn not only recruit more neutrophils but a host of other immune cells to
the injury site [48, 50]. It is therefore essential to carefully dissect the aspects of
neutrophil functions to generate a well-balanced anti-viral therapy.
Natural Killer (NK) cells: NK cells are generally recruited between the time of
neutrophil and T cell infiltration following a virus infection [51]. NK cells can
differentiate between normal cells and virus-infected cells by up/downregulation of
their unique receptors (inhibitory and activating) [52]. They are cytotoxic in function,
killing virus-infected lung epithelial cells by secretion of IFN-γ and Granzyme B [51,
53]. Also, NK cells engage in a unique antibody-dependent cell-mediated
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cytotoxicity (ADCC), in which antibodies bind to viral particles on infected cell
surfaces, marking them for clearance via cell death [40, 41, 43, 51]. Most NK cell
depletion studies are associated with an increased viral burden in mouse lungs and
enhanced disease severity, implicating their role in controlling virus infection [51].
However, NK cells producing IFN-γ have also been shown to be injurious to lung
epithelium during RSV infection [54]. Further, several influenza virus strains are
shown to evade NK cell-mediated killing by activating the inhibitory receptor
signaling that prevents the infected cells from being marked for death [55]. Hence,
optimal NK cell activity seems to be dependent on virus strains for effective viral
clearance from lungs or lung pathology [51].
Invariant Natural Killer T (iNKT) cells: Representing a diverse group of T
cells that have the capacities of both NK and T cells is iNKT cells, which express a
unique CD1d receptor on their cell surface that recognizes self-lipids during
respiratory viral infections [36, 45, 53]. iNKT cells can perform effector responses by
cytotoxic activities and secretion of cytokines. iNKT cells have been shown to boost
early immune responses, reducing viral titers, and also controlling inflammatory
monocytes in a highly pathogenic influenza mouse model [40, 53, 56]. CD1d
deficient mice infected with influenza also showed that iNKT cell led IFN-γ
production was necessary for optimal NK cell and CD8+ T cell activity [56]. Overall,
iNKT cells appear to be mostly beneficial in controlling acute respiratory virus
infection.
Lymphocytes
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B and CD4+ T cells: The primary function of B cells in virus infections is to
produce virus-specific antibodies that can neutralize, inactivate, and opsonize viral
particles and also initiate other adaptive immune mechanisms that ultimately lead to
viral clearance [35, 40]. The presence of neutralizing antibodies to rhinovirus and
influenza in the serum has been correlated with protection from disease severity in
patients [15, 16, 19, 20, 57]. Neutralizing antibodies prevent infection of respiratory
epithelium by blocking viral surface proteins from attaching to the host cell receptors,
and binding to infected cells marking them for death by ADCC [35, 58]. Another antiviral mechanism of antibodies is to tag the virus for inactivation by the complement
system and phagocytosis by macrophages and/or neutrophils (antibody-dependent
cellular phagocytosis; ADCP) [35]. For an effective B cell response during viral
infection, CD4+ follicular T helper (Tfh) cells are required as they help in maturation
and proliferation of neutralizing antibody-producing B cells in secondary lymphoid
organs. The presence of Tfh cells after vaccination in young adults is correlated with
the production of influenza-specific IgG and IgM antibodies [15, 17, 20, 57]. While B
cells have proven to be largely useful for generating anti-viral immunity, the partial
cytotoxicity required for viral clearance results in untoward consequences to the
physiology of the epithelium.
CD8+ T cells: Numerous studies on CD8+ T cells' role in respiratory virus
infections have shown them to be essential for viral clearance by cytotoxicity of
infected cells. This is clearly shown in studies using athymic and/or Rag1-/- mice
which display impaired virus clearance and, therefore, do not recover from the
infections [59-61]. Similarly, adoptive transfer of influenza-specific activated CD8+ T
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cells into SCID mice led to reduced virus load and enhanced mouse survival [35,
57]. To induce cytotoxicity of infected cells, CD8+ T cells use a variety of
mechanisms such as engagement of death receptors expressed on virus-infected
cells and release of cytotoxic factors like perforin and granzyme B to create holes in
the cell membrane and initiate apoptosis of infected cells [40]. Despite the essential
functions of CD8+ T cell-mediated viral clearance, the respiratory epithelium is
significantly compromised if CD8+ T cell response is unregulated and can lead to
catastrophic damage to the host. This is substantiated by multiple studies in Rag1-/mice displaying delayed lung injury and mortality of influenza infections [59, 61-63].
Further, the adoptive transfer of RSV-specific CD8+ T cells in Rag1-/- mice led to
increased morbidity and mortality [63]. Additionally, CD8+ T cell depletion studies
showed impaired viral clearance but decreased lung injury [60, 61, 63, 64]. While the
adaptive immune response to virus infections is essential for the resolution of
infection and creates a long-term memory response against secondary infections,
but if unregulated it can cause sufficient damage leading to host death.

1.6 Host survival of viral pneumonia
The primary goal for protection against viral pneumonia associated illness is
host survival. One way of achieving host survival is to enhance virus elimination from
the host, a concept termed ‘host resistance’ [65, 66]. The other way is to mitigate
damage to host tissues caused by a virus infection, a concept termed ‘host
tolerance’ [65, 66]. Most host leukocytes promote viral clearance by apoptosis of
virus-infected cells causing excessive inflammation to the extent of destroying lung
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physiology, resulting in acute respiratory distress and ultimately host death. Often,
the factor that is required for viral clearance is also the cause for immunopathology,
as was discussed earlier in this chapter about several leukocytes involved in
controlling viral infections. Therefore, it is important to consider interventions that
can eliminate the virus (host resistance) and control the damage done by the
resistance mechanisms (disease tolerance), thereby enhancing host survival of viral
infections [65-68]. Incidentally, lung epithelial cells, the target of most respiratory
viruses, possess their own anti-viral defense mechanisms that have been largely
overlooked as an alternative intervention against virus infections and related
immunopathology [33]. Therefore, we will now discuss the lung epithelium defense
mechanisms and how they can be harnessed to control viral infections and prevent
chronic virus-induced asthma.

1.7 Anti-viral defense of respiratory epithelium
The lung epithelium for a long time was considered only essential for
maintaining structural integrity and carrying out the function of gas exchange in the
lungs. However, accumulating evidence suggests that lung epithelial cells are
capable of mediating host defense against pathogens [69, 70]. Airway epithelial cells
can enhance the host’s barrier defense by the production of mucus, anti-microbial
peptides, and reactive oxygen species (ROS) in response to several inflammatory
insults, including viruses [71-73]. In addition to direct pathogen killing, alveolar
epithelial cells communicate with the resident lung leukocytes by secretion of
cytokines and chemokines that recruit leukocytes from lymphoid organs to the site of
13

infection [43, 45, 74]. While the epithelium signaling capacity to leukocytes has been
explored, the innate anti-microbial capacity has received extraordinarily little
attention. Our lab and several others have explored the inducibility of epithelial cells
to kill pathogens as an important mechanism of innate resistance to infection.
Therefore, further understanding of epithelial manipulation-based intervention is
warranted for the prevention and treatment of various respiratory diseases.
Innate immune sensing of respiratory viruses: The lung epithelium, acting
as an interface between the environment and the host, is constantly exposed to
pathogens. Respiratory epithelial cells can recognize various pathogens through
pathogen recognition receptors (PRRs) signaling on the plasma membrane or within
endosomal vesicles [75, 76]. PRRs recognize specific conserved microbial patterns,
collectively referred to as pattern-associated molecular patterns (PAMPs) [58, 75].
The lung epithelial cells express a variety of membrane and cytosolic PRRs such as
Toll-like receptor (TLR), NOD-like receptor (NLR), C-type lectins, and retinoic acid
inducible gene-I (RIG-I) among various other sensors. However, since this thesis
project is focused on TLR stimulation mediated anti-viral immunity, we will only
discuss TLR mediated immune sensing and anti-viral signaling. The lung epithelium
expresses all known human TLRs including ones expressed on the plasma
membrane and in the endosomes [75]. Viral proteins are recognized by cell surface
TLRs 2 and 4 [76]. Intracellular TLRs 3, 7, 8, and 9 located in endosomes recognize
viral nucleic acids [76]. TLR activation upon virus detection leads to recruitment of
cytosolic Toll/IL-1R (TIR) adaptor proteins such as MyD88 (utilized by all TLRs
except TLR 3), TRIF (utilized by TLR 3 and 4) or TRAM (utilized by TLR4) to the
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cytosolic TLR domain [76]. These signaling cascades lead to the assembly of the
Myddosome complex comprising of different IRAK and TRAF proteins, which
eventually signal through NF-κB, activating the transcription of pro-inflammatory
cytokines such as type I IFN [76]. TLR sensing of the virus eventually leads to the
production of anti-viral proteins in epithelial cells and the production of cytokines and
chemokines leads to the recruitment of innate and adaptive immune cells which
ultimately clear the virus.
Physical Barrier: The lungs’ mucosal surface is almost entirely covered with
epithelium and consists of tight junctions (TJs), desmosomes, gap and adherens
junctions (AJs) which regulate cell-cell activity [36, 69, 77]. TJs are important to
maintain epithelial integrity and ensure communication between cells. AJs are
located below TJs providing adhesive contacts for neighboring cells. Gap junctions
are channels located between cells that allow ions and small metabolites to diffuse
between cells. Desmosomes are intercellular junctions that form strong adhesive
bonds between cells providing mechanical strength [36, 69, 77]. Therefore, by
forming a strong physical barrier and the network of junctions between cells, the
epithelium provides efficient first-line defense against viruses. Further, the
mucociliary apparatus provides another layer of mucosal protection by trapping
pathogens in the mucus and expelling them from the lungs with the aid of cilia [36,
70, 77]. To maintain tissue homeostasis, goblet cells of the epithelium continuously
secrete mucus, mainly consisting of mucins made of glycoproteins to form a
structural network and produce anti-viral substances [36, 69, 73, 78]. While
increased mucin production during viral infections helps in viral elimination,
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continuous and excessive airway mucus production can lead to airway obstruction, a
prominent feature of asthma [79].
Type I and III interferons: Activation of type I interferons (IFN) is one of the
main results of TLR recognition of virus infections [76]. For many years, TLRmediated signaling leading to IFN production was mainly studied in phagocytic cells
and the contribution of epithelial cells was less certain [36, 58, 75, 80]. However, it is
now known that almost all cell types, including lung epithelial cells, can produce type
I interferons. Most TLR signaling events have been linked to Interferon regulatory
factor (IRF) 3 and IRF7 activating IFN stimulated genes (ISGs) that in turn code for
anti-viral proteins [36, 73]. These ISGs encode for different anti-viral proteins such
as Mx1, PKR, and Oas1, among several others, which function to control viral
replication by inducing an anti-viral state [81]. For example, mouse studies showed
Mx1 inhibits viral replication by blocking viral RNA transcription and a deficiency of
this protein leads to susceptibility to influenza infection [82]. Similarly, Oas1 enzyme
activates latent ribonuclease (RNAse L) resulting in viral RNA degradation and
inhibition of protein synthesis [83].
Another group of IFNs called type III interferons are secreted by epithelial cells
in different mucosal surfaces [37]. Both types of IFNs are known to induce ISGs that
in turn trigger anti-viral peptide generation, apoptosis of infected cells, and activation
of different immune cell pathways resulting in the recruitment of innate and adaptive
immune cell types [81, 84, 85]. Increasing evidence suggests that type III IFNs are
the dominant IFN response in the airways, especially under type I IFN deficiency
[37, 86]. While type I IFNs are also known to induce immunopathology during viral
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infections, type III IFNs are known to only induce an anti-viral state without much
damage to the host [81, 84, 86, 87]. However, both type I and III IFNs appear to be
important for viral clearance, and depletion or lack of either type of IFNs results in
increased viral replication and impaired viral clearance leading to increased mortality
from viral infections [37, 45, 76, 81, 84, 87].

Reactive Oxygen Species: The lung epithelium also produces ROS primarily
by mitochondrial, NADPH oxidase (NOX), and Dual oxidases (Duox) sources in
response to infectious stimulus [88-93]. Hydrogen peroxide and superoxide can
promote virus elimination either directly by oxidative damage to virus particles or
indirectly by acting as signaling molecules to promote innate and adaptive immune
mechanisms [88, 92, 93]. Superoxide derived from NOX2 in epithelial cells can
promote cell death by autophagy [92]. High ROS levels can reinforce the repression
of mammalian target of rapamycin (mTOR) by activation of AMP-activated kinase
(AMPK) [92]. Inhibition of the mTOR pathway is known to reduce viral burden by
inducing autophagy, cell death of infected reservoirs, and regulating CD8+ T cell
memory [92]. However, most of these mechanisms of ROS-mediated anti-viral
activity are derived from studies focusing on phagocytes such as neutrophils and
macrophages. The ability of the lung epithelium in generating ROS as an anti-viral
defense mechanism has not been explored significantly. We will cover this area of
investigation in Chapter 6 on anti-viral mechanisms by lung epithelial cells.

Enhanced recruitment of host leukocytes: After virus sensing by TLR
recognition, lung epithelial cells secrete a variety of proinflammatory cytokines and
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leukocyte recruiting chemokines. These include cytokines like TNF-α, IL-1β, IL-6,
GM-CSF, and chemokines like CXCL5, CXCL2, CCL20 that recruit neutrophils,
macrophages, NK cells to the site of infection [89]. This process certainly is required
for the host immune response to clear the virus. However, beyond the function of
alerting the host immune system for viral clearance, epithelial cells produce
cytokines like IL-33, IL-25, and TSLP that particularly promote T helper 2 adaptive
immune response that in many cases can turn maladaptive [6, 9, 94]. Production of
epithelial IL-33 represents a potential link to airway CD4+ Th2 type inflammation
associated with asthma. So far, mouse studies have indicated a correlation between
IL-33 deficiency and failure in dendritic cell (DC) activation and migration to the
draining lymph nodes [79, 95-98]. Several studies have shown IL-33 activated DCs
when adoptively transferred exacerbate lung inflammation in allergen-induced
asthma mouse models [99-101]. Therefore, epithelium targeted therapies seem to
be a rational approach to controlling lung inflammation caused by epithelial IL-33
response upon virus or allergen assault.

1.8 Inducible epithelial resistance
Since respiratory epithelium is the target for many viruses, our lab hypothesized
that the epithelium can be alternately harnessed to stimulate the local lung innate
immune defense mechanisms. Although innate immune activation in the lungs is low
at baseline, as reflected by the low level of anti-microbial activity without prior
stimulation, there is generous evidence about the inducibility of local lung epithelial
cells to perform anti-microbial activities traditionally carried out by leukocytes [36, 43,
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69, 70, 77]. In this regard, our lab used this evidence and found that local stimulation
of the lung microenvironment in mice with nontypeable Haemophilus
influenzae (NTHi) lysate leads to broad resistance against multiple pathogens [7173, 102, 103]. This broad resistance against various pathogens occurred rapidly
within hours of aerosolization and did not rely on adaptive immune response [71].
This bacterial lysate-induced broad resistance was dependent on TLR signaling
[103]. All TLR signaling requires adaptor proteins such as MyD88 or TRIF [76]. We
found that NTHi-induced resistance was MyD88 dependent and not TRIF dependent
[103]. This evidence of MyD88 dependency of innate resistance focused our future
studies on TLRs among all PRRs. But, the lack of TRIF-dependent effect of the
protection indicated that only a few TLR subsets were necessary for inducible
resistance. This provided the basis for testing different synthetic TLR ligands in
combination against multiple pathogens. However, individual TLR ligands failed to
induce a strong resistance against pneumonia [103]. Therefore, to determine
whether a combination of TLR ligands conferred protection, 21 non-redundant
combinations of the several synthetic TLR ligands were tested in mice against
pneumonia. Although not all tested TLR agonist combinations protected against
pneumonia, a few combinations provided the protection that was statistically
significant than PBS treatment [103]. However, no combination was as superior or
effective as the combination of TLR2/6 (Pam2CSK4) and 9 (ODN2395) which
resulted in 100% mouse survival against bacterial pneumonia [72, 102, 103].
Similarly, pathogen killing was associated with a synergistic combination of
Pam2CSK4 and ODN2395 [103]. Further, the lab found that class C ODNs and not
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class A or B ODNs provided synergistic interactions with Pam2CSK4 for maximum
resistance against bacterial pneumonia [103]. An explanation for this phenomenon
may come from the functions and structure of class C CpG ODNs. Class C ODNs
have characteristics of both class A and B ODNs, and it may be hypothesized that
stimulation with Class C ODN results in both IRF-7 and NF-κB pathways required for
the protective Pam2-ODN effect. Interestingly, by fluorescent microscopy, we found
that Pam2CSK4 and ODN2395 co-localize intracellularly in endosomes in lung
epithelial cells [103]. To this effect, several studies have shown that TLR2 and TLR9
cooperate in controlling several pathogens including Mycobacterium tuberculosis,
Helicobacter pylori, and herpes simplex virus [104-106]. However, further studies are
required to uncover the synergistic interactions of TLR 2 and 9 signaling
components.
To date, our lab has shown that mouse inhalation of an aerosolized
combination of Pam2CSK4 and a class C ODN-M362 (together this combination is
called Pam2-ODN) led to resistance against respiratory pathogens including viruses
[71, 72, 102, 107, 108]. Further, we have shown that stimulated innate resistance
with Pam2-ODN in the lungs is dominantly carried out by the epithelium as antimicrobial resistance is still intact in mice deficient of individual leukocytes
(neutrophils, macrophages, dendritic cells, NK cells, and lymphocytes) [102]. This is
further supported by mice showing no resistance against other treatment routes
(intraperitoneal or intravenous) suggesting that resistance mechanisms are local [72,
73]. In addition, mice conditionally deleted of MyD88 (required for TLR signaling)
only in lung epithelial cells showed no benefit from Pam2-ODN stimulation, strongly
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indicating the role of lung epithelial cells in driving the protective Pam2-ODN
response [102, 103]. Further, in vitro stimulation of isolated lung epithelial cells with
bacterial lysates or Pam2-ODN showed efficient pathogen killing ability [107, 109].
Therefore, our lab described this broad innate resistance as ‘Inducible epithelial
resistance’.
This evidence of the inducibility of lung epithelial cells to efficiently kill
pathogens seems a rational approach to treating respiratory virus-related illness. In
this thesis project, we will focus on uncovering mechanisms of enhanced survival of
respiratory virus infections by therapeutic stimulation of lung epithelial cells to initiate
anti-viral effects. Further, we also focus on the prevention of virus-induced chronic
asthma-like disease by viral killing and viral-killing independent mechanisms.
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Chapter 2: Specific Aims
2.1 Working model and hypothesis
Using the knowledge on cooperative abilities of TLR signaling to induce
protective responses, our lab found that combinatorial treatment with TLR2/6 (Pam2CSK4) and TLR 9 (ODN-M362) agonists showed the maximal protection against a
broad set of pathogens [71, 72]. Further, we have shown prevention of chronic virusinduced asthma in mice treated with Pam2-ODN [110]. However, the mechanisms
underlying protection against viral pneumonia-related mortality, chronic asthma-like
disease, and anti-viral killing mechanisms by Pam2-ODN stimulation of lung
epithelial cells has not been fully elucidated by our group. Therefore, this thesis
project will focus on understanding three aspects of respiratory virus infections – 1)
enhancing the host survival during viral infections, 2) preventing virus-induced
asthma-like disease, and 2) uncovering virus-killing mechanisms by Pam2-ODN
stimulation of lung epithelial cells. The central hypothesis of this project is that
“Inducible epithelial resistance enhances mouse survival of respiratory viral
infections by reducing viral burden by epithelial ROS production and prevents
progression to virus-induced asthma-like disease by controlling IL-33
production”. To address this hypothesis, studies under the following aims will be
performed.
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2.2 Specific Aims
Aim 1: Determine Pam2-ODN mediated enhanced survival of viral
pneumonia in mice. Rationale and Hypothesis: Several studies have indicated that
the host immune response during viral infections is often also the cause of fatal
immunopathology [21, 65, 66]. And, our preliminary studies using the SeV mouse
model have shown that peak mortality of SeV pneumonia occurs at the time of
lymphocytic lung inflammation. I hypothesize that CD8+ T cell inflammation
contributes to mouse mortality of SeV pneumonia which can be prevented by Pam2ODN pretreatment and we will address this hypothesis in three sub aims 1a)
Determine the kinetics of CD8+ T cells in Pam2-ODN treated and untreated SeVinfected mice. 1b) Identify the antiviral and immunopathology causing role of CD8+ T
cells by depletion studies. 1c) Determine the role of Pam2-ODN induced ROS in
reducing the lymphocytic inflammation during SeV infection.
Aim 2: Determine mechanisms of Pam2-ODN mediated prevention of
virus-induced asthma. Rationale and Hypothesis: Our lab has previously shown
that Pam2-ODN aerosolization in mice protects against SeV-induced asthma-like
disease with reduced airway hyperreactivity, mucus metaplasia, and eosinophils.
Interestingly, asthma is also reduced in mice aerosolized with Pam2-ODN after viral
clearance by viral-killing independent mechanisms, which are not elucidated.
Therefore, I hypothesize that Pam2-ODN treatment after SeV clearance can reduce
asthma by reducing lung IL-33. To address this hypothesis, studies under the
following sub aims will be performed. 2a) Determine the kinetics of IL-33 reduction in
mice treated with Pam2-ODN and SeV challenged. 2b) Determine the cellular
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source of IL-33 in lung cells during SeV infection. 2c) Determine whether IL-33 is
reduced in SeV challenged mice treated with Pam2-ODN after viral clearance.
Aim 3: Determine the viral-killing mechanisms of Pam2-ODN treatment in
lung epithelial cells. Rationale and Hypothesis: Our lab has reported that Pam2ODN induced ROS is essential for protection against viral infections in vivo and in
isolated lung epithelial cells. I hypothesize that Pam2-ODN induced ROS directly
inhibits SeV particles thereby reducing SeV replication in the lung epithelial cells. To
address this hypothesis, studies under the following sub aims will be performed. 3a)
Determine whether Pam2-ODN reduces SeV burden before or after SeV entry in
lung epithelial cells. 3b) Determine the role of Pam2-ODN-induced ROS in SeV
inactivation before or after SeV entry in lung epithelial cells.
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Chapter 3: Materials and Methods
The following chapter is based on my publications, used with permission granted by
mBIO and British Journal of Pharmacology and American Thoracic Society.
Copyright © 2019 Kirkpatrick et al
Kirkpatrick, C.T., Y. Wang, M.M. Leiva Juarez, P. Shivshankar, J. Pantaleon Garcia,
A.K. Plumer, V.V. Kulkarni, H.H. Ware, F. Gulraiz, M.A. Chavez Cavasos, G.
Martinez Zayes, S. Wali, A.P. Rice, H. Liu, J.M. Tour, W.K.A. Sikkema, A.S. Cruz
Solbes, K.A. Youker, M.J. Tuvim, B.F. Dickey, and S.E. Evans, Inducible Lung
Epithelial Resistance Requires Multisource Reactive Oxygen Species Generation To
Protect against Viral Infections. MBio, 2018. 9(3).
Reprinted with permission of the American Thoracic Society.
Copyright © 2020 American Thoracic Society. All rights reserved.
The American Journal of Respiratory Cell and Molecular Biology is an official journal
of the American Thoracic Society.
(https://www.atsjournals.org/doi/10.1165/rcmb.2020-0241OC)
Wali, S., J.R. Flores, A.M. Jaramillo, D.L. Goldblatt, J. Pantaleon Garcia, M.J. Tuvim,
B.F. Dickey, and S.E. Evans, Immune Modulation to Improve Survival of Viral
Pneumonia in Mice. Am J Respir Cell Mol Biol, 2020.
Copyright © 2020 British Journal of Pharmacology
https://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=97fcf6ae-454f-492e-a5a7bfec333d5889
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Goldblatt, D.L., J.R. Flores, G. Valverde Ha, A.M. Jaramillo, S. Tkachman, C.T.
Kirkpatrick, S. Wali, B. Hernandez, D.E. Ost, B.L. Scott, J. Chen, S.E. Evans, M.J.
Tuvim, and B.F. Dickey, Inducible epithelial resistance against acute Sendai virus
infection prevents chronic asthma-like lung disease in mice. Br J Pharmacol, 2020.
177(10): p. 2256-2273.
3.1 Mice and cell culture
All in vivo experiments were performed using 6- to 10-week-old C57BL/6J mice
of a single-sex (male or female) purchased from (Jackson laboratory) or bred inhouse according to the Institutional Animal Care and Use Committee of MD
Anderson Cancer Center, protocol 00000907-RN01. Mouse lung epithelial (MLE-15)
cells were kindly provided by Jeffrey Whitsett, Cincinnati Children’s Hospital Medical
Center, and cultured in DMEM with 2% Fetal Bovine Serum (FBS), 1% insulin, and
transferrin. MLE-15 cells were authenticated by the MD Anderson Characterized Cell
Line Core Facility. To harvest tracheal epithelial cells, mice were anesthetized to
expose and excise tracheas. These tracheas were then digested in pronase (1.5
mg/ml, Sigma Aldrich) overnight at 4º C. Tracheal epithelial cells were then isolated
and cultured on collagen-coated transwells in Ham’s F12 media supplemented with
differentiation growth factors and hormones as previously described [111].

3.2 TLR treatments and viral challenge
For in vitro treatments, cells were treated with Pam2CSK4 (2.2 µM) and ODN
M362 (0.55 µM), 4 h before SeV inoculation as previously described (ref). For in vivo
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treatments, 10 ml solution of Pam2CSK4 (4 µM) and ODN M362 (1 µM) in endotoxinfree water was delivered by Aerotech II nebulizer (Biodex Medical Systems) driven
by 10 l/min along with CO2 (5%) in air for 30 minutes as previously described [112].
SeV was purchased from ATCC (Manassas, VA) and grown in Rhesus monkey
kidney cells obtained from Cell Pro labs (Golden Valley, MN). For in vitro challenges,
multiplicity of infection (MOI) = 1 was used. Unless otherwise stated, mice were
challenged with 1 x 108 plaque-forming units (pfu) in PBS inserted into the
oropharynx of mice, under isoflurane anesthesia as described [110]. Mice were
weighed before and daily after challenge as a measure of morbidity and criteria for
euthanasia.

3.3 Bronchoalveolar lavage and differential Giemsa staining
After deep anesthesia, mouse tracheas were exposed, cannulated with a 20gauge syringe, and instilled with 1.5 ml of PBS. Approximately 1 ml of BAL fluid was
collected per sample. The BAL fluid was then spun down at 4º C at 300 g to collect
the cells in the pellet. The cell pellet was resuspended in 1 ml of ice-cold PBS and
200 μl of this cell suspension was then subjected to cytocentrifugation at 300 g for 5
min. Cells were stained with Giemsa stain for differential count determination and
total cells were counted by hemocytometer.

3.4 Flow cytometry
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For in vivo experiments, mouse lungs were perfused with 5 to 10 ml ice-cold
PBS, dissected, cut into 1 mm3 piece, and digested with collagenase/DNAse I (5
mg/ml, Worthington biochemical) for 30 min at 37° C. After digestion, single cells
were collected by passing through a 70 µm filter. These single cells were washed
with FACS staining buffer (PBS supplemented with 1% FBS) and stained for specific
cell types, as indicated in the antibody table (Table 1). For in vitro experiments,
MLE-15 cells were seeded on 24 well plates for treatment with Pam2-ODN and SeV
inoculation. Cells were trypsinized and washed with FACS staining buffer 2X. Cells
were blocked in 5% donkey serum for 30 min before proceeding to stain with Rabbit
SeV antibody (MBL International) overnight at 4° C, followed by staining with
secondary Alexa488 anti-rabbit antibody (Jackson Immunologicals) for 1 h. Cells
were fixed and acquired on BD LSRII (BD Biosciences) for Alexa488 positive cells.

3.5 SeV Immunofluorescence
MLE-15 cells were grown on chamber slides (Labtek), treated with Pam2-ODN
for 4 h before inoculation with SeV (MOI 1). Cells were then fixed with 2%
paraformaldehyde before staining with a rabbit anti-SeV antibody (MBL
International) and detected using a secondary anti-rabbit antibody. For each
experimental condition, specimens were imaged using an Olympus BX60
microscope using identical parameters for time of exposure, color intensity, contrast,
and magnification. Images were then loaded on ImageJ software to calculate the
mean fluorescence intensity for each group.
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3.6 Hematoxylin and eosin staining
Mouse lungs were fixed by intratracheal inflation with 10% formalin for 24 h,
and then transferred to 70% ethanol embedded in paraffin. Tissue blocks were then
cut into 5 µm sections, mounted onto frosted glass slides, deparaffinized with xylene,
washed with ethanol, then rehydrated and stained with hematoxylin and eosin for
morphological changes.

3.7 Epithelial proliferation assays
Mice were injected intraperitoneally with 0.1 ml EdU (1 mg/mouse). After 24 h,
mouse lungs were inflated and fixed with 10% formalin for 24 h at 4° C, and then
lungs were embedded in paraffin. Paraffin sections were cut into 5 µm transverse
sections of the axial airway, between lateral branches 1 and 2. Lung sections were
then stained following the Click-iT EdU Imaging Kit protocol for EdU (Abcam,)
followed by staining with DAPI for 30 min at room temperature. Images were
collected using an Olympus BX60 microscope using identical parameters for all
conditions. Some lung sections were subjected to antigen retrieval and then stained
for Ki67 (1:1000; Invitrogen) or cCasp3 (1:500; Cell Signaling). EdU, Ki67, or
cCasp3 positive cells were quantified using a cell counter plugin in ImageJ and
normalized to DAPI positive cells in every field of view (number of fields surveyed
per mouse sample = 3).
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3.8 CD8+ T cell depletion
Anti-CD8-β antibody (200 µg/mouse, Bioxell) was delivered to mice
intraperitoneally at indicated time points. CD8+ T cell depletion was confirmed by
flow cytometry analysis 24 to 48 h after depletion.

3.9 Viral burden quantification
For in vivo experiments, mouse lungs were collected 5 days after SeV
challenge. RNA from mouse lungs was extracted using the Qiagen RNeasy kit. 500
ng of total RNA was converted to cDNA using Biorad iScript cDNA conversion kit.
Viral burden was determined by reverse transcription quantitative PCR (RT-qPCR)
of the Sendai Matrix (M) protein normalized to house-keeping gene 18SRNA. 18S
forward primer – GTAACCCGTTGAACCCCATT; reverse primer –
CCATCCAATCGGTAGTAGCG. SeV M gene forward primer –
ACTGGGACCCTATCTAAGACAT; reverse primer –
TAGTAGCGGAAATCACGAGG. The Limit of quantification (LOQ) was established
for the SeV qPCR assay as the highest dilution of the template still maintaining the
linearity of the assay. The threshold cycle (CT) value of the LOQ was set as the
lower limit for the assay.

3.10 ROS inhibition in vitro and in vivo
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NADPH oxidase activity was inhibited by exposing the cells to GKT137831
(10 µM; Selleckchem) 12 h prior to treatment with Pam2-ODN or PBS. Mitochondrial
ROS production was inhibited using the combination of FCCP (400 nM, Cayman
Chemicals) and TTFA (200 µM, Cayman Chemicals) for 1 h before Pam2-ODN or
PBS treatment. For in vivo experiments, mice were aerosolized with 10 ml TTFA
(200 mM) and FCCP (800 µM) 2 h before Pam2-ODN aerosolization and 2 h before
SeV challenge and then again 4 days after SeV challenge.

3.11 Viral attachment assays
For most enveloped viruses, internalization into epithelial cells is inhibited at 4º
C without affecting viral binding to epithelial cells [34]. MLE-15 cells were cultured in
24 well plates or chamber slides for treatment with Pam2-ODN for 4 h. Cells were
placed on ice 30 min before inoculation with SeV to prevent viral entry into the cells.
After 4 h inoculation on ice, cells were vigorously washed 5X with media to remove
unattached virus. Cells were then harvested to measure SeV burden using
immunofluorescence or flow cytometry. For RT-qPCR assays, epithelial cells were
treated with Pam2-ODN or PBS, followed by SeV infection on ice (to prevent viral
entry into cells). Virus particles were allowed to attach to the epithelial targets for 4 h
on ice. These cells were then extensively washed to remove unattached virus
particles, and then the cells were lysed by passing through a syringe 10X. The
liberated virus particles were then transferred to naïve epithelial cells that had no
prior exposure to Pam2-ODN. SeV M gene expression was assessed by qPCR after
24 h of SeV replication in the new cells. In some experiments, mitoROS inhibitors
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(FFCP-TTFA) were used before Pam2-ODN treatment to determine the role of
Pam2-ODN induced ROS in SeV inactivation prior to internalization.

3.12 IL-33 Immunohistochemistry
Mouse lungs were fixed, embedded, sectioned, and deparaffinized, then
exposed for 10 min to 3% H2O2 in 90% methanol, and then heated for 10 min in 10
mM sodium citrate, pH 6.0, for antigen retrieval. Slides were rinsed in water, blocked
in horse serum (Jackson ImmunoResearch, West Grove, PA) for 1h, then rinsed
again and incubated with goat anti-mouse IL-33 (R&D Systems, Minneapolis, MN;
1:1000) diluted in blocking solution at 4° C overnight. After incubation, secondary
antibody - biotinylated horse anti-goat IgG (Vector) was added for 2 h at room
temperature. Tissue sections were then washed with PBS, counterstained with H&E,
and mounted with VectaMount (Vector).

3.13 IL-33 Immunofluorescence
Lungs were frozen in OCT and cut into 10-µm sections. Sections mounted on
glass slides were thawed, washed with water, blocked with donkey serum (Jackson
ImmunoResearch), then incubated with primary antibodies overnight at 4°C. Primary
antibodies used were: rabbit anti-prosurfactant protein C (EMD Millipore, Burlington,
MA; 1:1000), rabbit anti-keratin 14 (KRT14, RB-9020-P0, Thermo Fisher, Waltham,
MA; 1:500), rat anti-mouse CD68 (BioLegend, San Diego; 1:200). This was followed
by the addition of secondary antibodies conjugated to Alexa 555 (Cy3), Alexa 488
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(FITC), and DAPI (Jackson ImmunoResearch) for 2 h. A confocal microscope
(A1plus, Nikon) was used to acquire all images. For quantitative studies, random
images were acquired by investigators blinded to subject identity. Percentages of IL33 positive cells were counted using ImageJ. To measure IL-33 fluorescence
intensity, the left lung was sectioned at the axial bronchus between lateral branches
1 and 2 using a precision cutting tool then imaged using an upright microscope
(Olympus BX 60) with a 40X lens objective and identical parameters of exposure
time, color intensity, contrast, and magnification. Images were uploaded to ImageJ,
and a red (IL-33) background intensity threshold was established by first measuring
fluorescence intensity for background regions (those without blue nuclear staining)
and regions of interest (double-positive red and blue staining). The threshold was
then set as the mean between maximal background regions and mean regions of
interest and subtracted from all fields.

3.14 Type I Interferon ELISA
Mouse tracheal epithelial cells were grown at an air-liquid interface. Cells were
treated with Pam2 and ODN as described earlier and infected with either influenza A
or SeV. Cell supernatants were collected at various times post-infection and used for
IFN-β ELISA (R&D Systems) according to the ELISA manufacturer’s instructions.

3.15 IL-33 ELISA
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Mouse lungs were snap-frozen in liquid nitrogen and stored in -80 ºC. Mouse
lung samples were homogenized in protein lysis buffer with protease inhibitors and
EDTA (Thermo Fisher). Homogenized samples were kept on ice for 30 mins to
separate the protein components from cell debris. Samples were then spun at high
speed at 4 ºC to collect the supernatant containing the total protein. Total protein
from the samples was measured using a BCA kit (Thermo Fisher) and 3 µg of total
protein was used for IL-33 ELISA (R&D Systems). The ELISA manufacturer’s
instructions were followed for the rest of the assay. Data collected was represented
as total protein per µg of tissue.

3.16 Statistics
All statistical analysis was performed using GraphPad Prism software (Version 8 for
Windows, GraphPad Software, La Jolla, CA). Data are representative of one
experiment from at least three independent experiments and presented as mean +/standard error of biological replicates. To determine pairwise differences in viral
burden or cell numbers, Student’s t-test was used. Mouse survival analysis of viral
challenges was analyzed using Log-rank, Mantel-Cox test. One-way analysis of
variance (ANOVA) with multiple comparisons was used to determined differences
between multiple experimental conditions.
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Table 1: List of antibodies used
Antibodies

Vendor

Catalog numbers

CD3

Tonbo

65-0031-U100

CD4

Tonbo

60-0042-U100

CD8

Tonbo

25-0081-U100

Live dead

Tonbo

13-0870-T500

CD25

Biolegend

102038

Foxp3 Treg kit

eBiosciences

72-5775

CD8-Depleting Ab

Bioxell

BE0223

CD19

Biolegend

115507

B220

BD Biosciences

562922

Anti-SeV virus Ab

MBL International

PD029

Ki67

Invitrogen

MA5-14520

cCasp3

Cell signaling

9662S
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Chapter 4: Determine Pam2-ODN mediated enhanced survival of viral
pneumonia in mice.
The following chapter is based on my publication, used with permission granted by
American Thoracic Society. The figures and data shown in this chapter are entirely
my work.
Reprinted with permission of the American Thoracic Society.
Copyright © 2020 American Thoracic Society. All rights reserved.
The American Journal of Respiratory Cell and Molecular Biology is an official journal
of the American Thoracic Society.
(https://www.atsjournals.org/doi/10.1165/rcmb.2020-0241OC)
Wali, S., J.R. Flores, A.M. Jaramillo, D.L. Goldblatt, J. Pantaleon Garcia, M.J. Tuvim,
B.F. Dickey, and S.E. Evans, Immune Modulation to Improve Survival of Viral
Pneumonia in Mice. Am J Respir Cell Mol Biol, 2020.

Our lab has previously found the survival benefit of Pam2-ODN aerosolization
in the influenza mouse model, but the mechanisms of host survival remain
incompletely elucidated [107]. Using the SeV mouse model, we found host mortality
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of infections occurring after viral clearance, as discussed in this chapter. Therefore,
to elucidate the mechanisms of host survival of viral pneumonia, we characterized
the cellular changes in the host occurring after infection in mice with or without
Pam2-ODN treatment and the results are presented below.

4.1 Pam2-ODN treatment enhanced mouse survival of SeV infections is
associated with reduced lung viral burden
Aerosolized Pam2-ODN treatment one day prior to SeV challenge increased
mouse survival of SeV challenge (Figure 1A) like the protection afforded against
lethal influenza pneumonia [107]. The survival benefit was associated with reduced
lung SeV burden, as measured by SeV M gene expression (Figure 1B).
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Figure 1: Pam2-ODN treatment enhanced mouse survival of SeV infections is
associated with reduced lung viral burden (A) Survival of mice treated with PBS
or Pam2-ODN one day prior to SeV virus challenge. (B) Mouse lung SeV burden 5
days after infection assessed by qPCR for Sendai Matrix (M) gene (Relative
quantification, RQ to 18S) relative to 18S. n=10 mice per group in survival plot (A),
n=4 mice/group in virus burden experiments. *p<0.05, **p<0.005.

4.2 Mouse mortality of SeV infections occurs after viral clearance from the
lungs
Investigating the natural progression of infection revealed that SeV lung burden
was maximal on day 5 and gradually decreased until falling below the limit of
quantification (LOQ) by day 11 (Figure 2A). Pam2-ODN pretreatment reduced SeV
burden on all assessed days (Figure 2A). Although the lethality of SeV infection was
exquisitely dependent on the inoculum size, we strikingly found that peak mortality
paradoxically occurred around days 10 to 12 after infection irrespective of inoculum
size, even though SeV is essentially undetectable that long after challenge (Figure
2A). This temporal dissociation between peak virus burden and peak mortality led to
the hypothesis that SeV-induced mortality may not be exclusively driven by
excessive virus burden but may also result from untoward SeV-induced host
immune response.
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Figure 2: Mouse mortality of SeV infections occurs after viral clearance from
lungs (A) Time course of lung SeV burden in mice treated with PBS or Pam2-ODN.
(B) SeV inoculum dependent mouse survival. Data are representative of three
independent experiments. n=10 mice per group in survival plot (B), n=4 mice/group
in virus burden experiments. LOQ, limit of quantification. *p<0.05.
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4.3 Pam2-ODN treatment reduces epithelial cell death and proliferation during
acute SeV infection
We found increases in lung epithelial cleaved caspase 3 (cCasp3), a marker for
programmed cell death, on days 7 to 11 after SeV infection (Figure 3A, upper panel).
Virus infection-related epithelial cell injury and death are typically associated with
proliferative repair mechanisms [113]. Staining the infected mouse lung tissue for
Ki67 and EdU revealed maximum signals for both markers in the second week after
infection (Figure 3B-E, upper panel). These events of lung epithelial cell death and
proliferation coincided with the peak of mortality (day 12, Figure 1E). Further,
hematoxylin and eosin staining of lung tissues infected with SeV showed profound
increases in inflammatory cells from days 7 to 10 with evidence of damaged airway
and parenchymal tissue (Figure 4). However, Pam2-ODN pretreatment of mice
reduced epithelial cell injury and proliferation (Figure 3A-E, lower panel). This
temporal association of epithelial injury and death after viral clearance supported the
hypothesis that mouse mortality caused by SeV infection is due in part to the host
immune response to SeV infections. Therefore, to explore this hypothesis, the host
leukocyte response to SeV infection was characterized.
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Figure 3: Pam2-ODN pretreatment reduces epithelial cell death and
proliferation during acute SeV infection. Cleaved caspase 3 (cCasp3) (A) or Ki67
(B) positive cells in mouse lung epithelium after SeV infection with or without Pam2ODN treatment (lower panel). n=5 mice per condition. Data are representative of two
independent experiments. Scale bar = 100 µm. *p<0.05.
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Figure 3 continued: Pam2-ODN pretreatment reduces epithelial cell death and
proliferation during acute SeV infection. EdU positive cells in axial (C), small
airways (D), and parenchyma (E) after SeV infection with or without Pam2-ODN
(lower panel). Data are representative of two independent experiments. Scale bar =
100 µm. *p<0.05.
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Figure 4: Mouse lung histology following SeV challenge with or without Pam2ODN.
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4.4 Pam2-ODN treatment reduces SeV induced lung CD8+ T cells.
Differential Giemsa staining of bronchoalveolar lavage (BAL) cells revealed
increased neutrophils on days 2 to 5 and increased macrophages on days 5 to 8
(Figure 5A, B, solid grey line) after SeV challenge. Congruent with our prior studies,
inhaled treatment with Pam2-ODN in the absence of infection led to a rapid rise in
neutrophils that was resolved within 5 days (Figure 5A, dashed line). The neutrophil
response to SeV challenge was modestly increased among mice pretreated with
Pam2-ODN (Figure 5A, solid dark line). Pam2-ODN-treated, SeV-challenged mice
showed almost no difference in macrophage number compared to PBS-treated,
SeV-challenged mice (Figure 5A, solid dark line). A rise in lymphocytes was
observed on days 8 to 11 in PBS-treated, SeV-challenged mice (Figure 5C, solid
grey line), temporally corresponding with peak mortality. However, Pam2-ODN
treated, SeV-challenged mice displayed significantly reduced lymphocyte numbers
at every time point assessed (Figure 5C, solid dark line). Specific lymphocytes (B
cells, CD4+, or CD8+ T cells) in the lungs of SeV infected with or without Pam2-ODN
were determined by flow cytometry showing only modest differences between the
groups [114]. The biggest difference between groups was in CD8+ T cells, with
Pam2-ODN-treated, SeV-challenged mice displaying a significantly lower number
and percentage of CD8+ T cells than PBS treated, SeV-challenged mice (Figure 5D,
E). Since the greatest difference after Pam2-ODN treatment was in CD8+ T cell
levels and there was a tight correlation between peak mortality and the increase in
lung CD8+ T cells on days 8 to 11, we investigated the role of CD8+ T cells in SeVinduced mortality.
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Figure 5: Pam2-ODN pretreatment reduces SeV induced lung CD8+ T cells.
Differential Giemsa staining of BAL cells showing (A) neutrophils, (B) macrophages,
and (C) lymphocytes from mice challenged with SeV with or without Pam2-ODN
pretreatment. Data are representative of three independent experiments. *p<0.05
compared to PBS+SeV.
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Figure 5 continued: Pam2-ODN pretreatment reduces SeV induced lung CD8+
T cells. (D) Flow cytometry for CD8+ T cells from disaggregated mouse lungs 11
days after SeV infection with or without Pam2-ODN. (E) Lung CD8+ T cells 11 days
after SeV challenge in mice pretreated with PBS or Pam2-ODN. Data are
representative of five independent experiments for (D) and (E). *p<0.05 compared to
PBS+SeV.
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4.5 Pam2-ODN treatment reduces CD8+ T cell-associated SeV induced
immunopathology
To understand the apparent contributions of host immunopathology to mouse
outcomes, we depleted CD8+ T cells on day 8 -- after virus burden was substantially
reduced but before peak mouse mortality (Figures 2A, 6A). Mice depleted of CD8+ T
cells displayed significantly enhanced survival of SeV challenge compared to mice
with intact CD8+ T cells (Figure 6B). Depletion of CD8+ T cells was confirmed by flow
cytometry in disaggregated lung cells 10 days after SeV challenge (Figure 6C). This
supported our hypothesis that CD8+ T cells contribute to fatal SeV-induced
immunopathology.
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Figure 6: Pam2-ODN treatment reduces CD8+ T cell-associated SeV induced
immunopathology. Experimental outline (A), survival (B), and percentage of CD8+
T cells (C) from disaggregated mouse lungs 10 days after SeV challenge following
pretreatment with PBS or Pam2-ODN and with or without CD8+ T cells depleted on
day 8 of SeV challenge. n=16 mice/group for survival in experiment A and n=4
mice/group in experiment (B). ****p<0.0001 compared to PBS in (C), ***p<0.0005
compared to PBS in (B) and (C), †p<0.05 compared to PBS, *p<0.05 compared to
PBS.
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4.6 Pam2-ODN treatment protects against SeV infections despite lack of CD8+
T cells
To assess the role of CD8+ T cells throughout infection, mouse CD8+ T cells
were depleted prior to and during SeV challenge (Figure 7A). This depletion resulted
in significantly reduced survival of SeV infection (Figure 7B), compatible with the
known antiviral functions of CD8+ T cells. However, it is notable that Pam2-ODN
treatment still significantly enhanced survival of SeV challenge even in the absence
of CD8+ T cells (Figure 7B). This finding was congruent with our previous studies
showing Pam2-ODN inducible resistance against bacterial pneumonia despite the
lack of mature lymphocytes (Rag1-/-).
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Figure 7: Pam2-ODN treatment protects against SeV infections despite the
lack of CD8+ T cells. Experimental outline (A), survival (B) of mice SeV challenge
following PBS or Pam2-ODN treatment, and with or without preinfection CD8+ T cell
depletion. **p<0.005 compared to PBS, #p<0.005 compared to α CD8 Ab-PBS,
†p<0.05 compared to PBS.
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4.7 Summary and discussion

While Pam2-ODN treatment provided a significant host survival benefit in SeV
infection, we observed this survival benefit occurring after the time when PBStreated mice had cleared the virus. This observation prompted the hypothesis that
host mortality is not the exclusive result of direct viral injury to the lungs, but due at
least in part to the host response to the virus infections. We observed enhanced
survival of SeV infections in mice depleted of CD8+ T cells 8 days after infection
(Figure 6), revealing the importance of balancing the dual functions of CD8+ T cells
in anti-viral immunity and in causing fatal immunopathology. Our findings suggested
that the surge in CD8+ T cells within the lungs after most virus has been cleared
causes physiologic impairment via lung injury and cell death [59, 61-63].

Previous reports support the concept of counter-balanced immune protection
and immunopathology by CD8+ T cells during virus infections [59, 62, 63]. Some
reports have shown that antigen-experienced memory CD8+ T cells enhance RSV
clearance, but also mediate severe immunopathology [59, 62-64]. However, our
study is the first to demonstrate the survival advantage in paramyxovirus respiratory
infection of either stimulating the lungs’ mucosal defenses early in the infection or of
suppressing the CD8+ T cells later in the infection. Our findings are also congruent
with reports on the role of CD8+ T cells in non-respiratory viral infection models, such
as in West Nile virus infection, where CD8+ T cell-deficient mice display decreased
mortality [61].
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While host survival of viral infections certainly improved by suppression of CD8+
T cell-associated immunopathology late in infection, some CD8+ T cell-depleted
mice were still susceptible to SeV infection i.e. we didn’t achieve 100% survival upon
depletion of CD8+ T cells on day 8 of SeV infection. This indicates there are other
mechanisms of virus-induced host mortality that play a complementary role to CD8+
T cell-associated immunopathology. These might include direct viral cytopathic
effects that result in epithelial apoptosis or secondary bacterial infections. Several
other virus infection studies in mice have suggested excessive activity of NK cells
and neutrophils to be associated with enhanced host mortality [48, 50].
Investigations to resolve the contributions of various factors in inducing host
mortality of virus infections will be the scope of future studies.
A limitation of our study is also in addressing the pathology of virus infections
that led to mouse mortality. Epithelial cell death and proliferation remain largely
associated with the timing of CD8+ T cell infiltration and mouse mortality peak.
Therefore, the next step in this area of research will be to address the effect of CD8+
T cell depletion on SeV-induced lung epithelial cell death and proliferation. I
hypothesize that the increase in SeV-induced epithelial cell death may reach a
threshold level where essential functions performed by lung epithelial cells are
impaired. To this effect, some groups have studied the failure of respiratory function
in mice infected with lethal influenza strains that succumb to the infection. Mice
infected with the PR/8 strain of influenza succumbed between days 9-12 (similar to
SeV infected mice in our model) with mortality corresponding to alveolar damage
reaching a threshold level beyond which the mice cannot survive [115]. Although
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there was no evidence of replicating virus on day 9 onward in infected mouse lungs,
the mouse mortality coincided with the loss of type I pneumocytes and reduced
ability to take oxygen and expel carbon dioxide from the infected lungs [115]. Thus,
poor gas exchange and reduced arterial blood oxygenation could eventually result in
compromised lung function leading to host death. These data indicating poor
respiration between days 9 to 12 also coincided with poor gross pathology in mice
characterized by necrotizing bronchiolitis, diffuse alveolar damage (DAD), fibrin
deposition, and hyaline membrane formation along the alveolar lining. Further, the
post-mortem report of patients that succumbed to influenza infection revealed DAD
with viral RNA present only in a few patients [116]. Another possible contributor to
poor respiration is the indirect effect of edema resulting from poor barrier function
[115, 117]. Sepsis is found to be associated with severe disease during viral
infections, which might result from secondary bacterial infections or a dysregulated
pro-inflammatory host response to virus infections. One study found that progression
to bacterial sepsis was 6 fold higher in patients with influenza pneumonia [118]. Data
collected from influenza-infected mouse models and infected humans support our
findings that mortality from respiratory virus infection results from a dysfunctional
immune response or impaired viral clearance. In this regard, a clear advantage of
Pam2-ODN treatment in mice is the rapid and robust reduction in lung viral burden
that leads to reduced host immune response (CD8+ T cells) and reduced epithelial
cell death. This is a clear advantage of early viral clearance enhancing mouse
survival by reducing the gross pathology of virus infections.
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While findings from our study and others reveal that the harmful effects of CD8+
T cell-mediated immunopathology may supersede the benefits of T cell-mediated
viral clearance, the question arises of what might be the adaptive value of the
vigorous late CD8+ T cell response. One possibility is that it might ensure that the
infection does not flare again, but that seems implausible since the host has
successfully defended itself against the initial infection, and innate immune
mechanisms presumably remain intact and are possibly primed [21, 24, 27], in
addition to the multiple adaptive immune mechanisms that increasingly come into
play. The possibility that the immunopathology simply results from an error on the
part of the immune system also seems implausible given the substantial rate of host
mortality, suggesting there is likely an adaptive value to the response. A third
possibility, that the persistence of pockets of low level infection might lead to chronic
lung pathology, is supported by a recent study showing that sites of viral RNA
remnants following influenza infection are linked to chronic lung disease [7]. Thus, a
trade-off may exist between the adaptive value of a vigorous CD8+ T cell response
to prevent chronic lung disease and the acute mortality it can cause. Manipulating
this balance therapeutically will need to account for both the benefits and costs of
the response. It is particularly appealing to develop inducible anti-microbial
strategies that do not rely on conventional T cell-mediated microbial clearance and
are also effective in vulnerable immune-deficient populations.
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Chapter 5: Determine mechanisms of Pam2-ODN mediated prevention of virusinduced asthma
The following chapter is based on my publication, used with permission granted by
the British Journal of Pharmacology. The figures and data shown in this chapter are
entirely my work.
Copyright © 2020 British Journal of Pharmacology
https://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=97fcf6ae-454f-492e-a5a7bfec333d5889
Goldblatt, D.L., J.R. Flores, G. Valverde Ha, A.M. Jaramillo, S. Tkachman, C.T.
Kirkpatrick, S. Wali, B. Hernandez, D.E. Ost, B.L. Scott, J. Chen, S.E. Evans, M.J.
Tuvim, and B.F. Dickey, Inducible epithelial resistance against acute Sendai virus
infection prevents chronic asthma-like lung disease in mice. Br J Pharmacol, 2020.
177(10): p. 2256-2273.

Our lab has found that SeV-induced asthma-like disease can be mitigated by
Pam2-ODN treatment one day prior to SeV challenge. While it is clear that the
treatment of mice with Pam2-ODN one day prior to SeV challenge reduced viral
burden (Figure 1, 2) and that probably directly had effects on reducing virus-induced
asthma-like symptoms (mucus metaplasia, airway hyperreactivity, and eosinophilia).
However, Holtzman and group showed that SeV infection in mice is translated into a
chronic asthma-like disease requiring a persistent IL-33 production in the lungs [6, 8,
9]. Therefore, our data showing reduced SeV induced asthma-like disease
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suggested that IL-33 may be reduced by Pam2-ODN treatment and it was important
to elucidate this in multiple ways and to understand the cellular source of IL-33
during SeV infection.
5.1 Pam2-ODN treatment reduces IL-33 production from lung cells during SeV
infection
We measured IL-33 protein levels in homogenized lung samples at different
times during SeV infection with or without Pam2-ODN to understand the time course
of IL-33 production in the lungs. We found that SeV infection leads to an increase in
IL-33 in mouse lungs from day 21 onward up to day 49 (Figure 8A-C) in comparison
to naïve mice or mice treated with Pam2-ODN alone. Of the time points assessed,
the highest IL-33 production by SeV infected mice was on day 49, with Pam2-ODN
treated SeV infected mice consistently reduced IL-33 production at all time points
(Figure 8A-C). By immunohistochemistry, we found naïve or Pam2-ODN alone
treated mice showed faint staining for IL-33 in lung cells. Mice challenged with SeV
without Pam2-ODN treatment showed a dramatic increase in the frequency and
intensity of IL-33 in the lung cells (Figure 8D). However, Pam2-ODN treated, SeV
challenged mice displayed drastically reduced IL-33 staining consistent with the
ELISA results from day 49 (Figure 8D). Further, to quantify the fluorescence intensity
of IL-33, we used immunofluorescence staining of mouse lung sections and found
Pam2-ODN treated SeV challenged mice displayed drastically reduced IL-33
intensity (Figure 8E).
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Figure 8: Pam2-ODN treatment reduces IL-33 production from lung cells
during SeV infection. IL-33 protein levels from homogenized mouse lungs at day
21 (A), 35 (B), and 49 (C) after SeV challenge with or without Pam2-ODN treatment,
determined by ELISA. *p<0.05 by unpaired Student's t ‐test.
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Figure 8 continued: Pam2-ODN treatment reduces IL-33 production from lung
cells during SeV infection. (D) Images of mouse lungs from day 49 with or without
SeV challenge and with or without Pam2-ODN treatment. The brown color is
immunohistochemical staining for IL‐33. Arrow points to an intensely stained Type 2
pneumocyte, and the arrowhead points to a faintly stained macrophage. Scale bar =
100 μm.
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Figure 8 continued: Pam2-ODN treatment reduces IL-33 production from lung
cells during SeV infection. (E) Same groups as in (D) showing quantification of
total IL‐33 immunofluorescence intensity. **p< 0.01 unpaired Student's t ‐test; n = 6–
8 mice, with three fields examined per mouse.
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5.2 SeV infection in mice leads to the production of IL-33 from mainly type II
alveolar epithelial cells.
Immunohistochemical staining for IL-33 in lung cells indicated localization
(corners of polygonal alveoli) and morphology (cuboidal and protruding into the
alveolar lumen) of type II alveolar cells (Figure 8B). This finding was congruent with
reports about substantial IL-33 expression in type II alveolar epithelial cells in naive
mice [119, 120]. Therefore, we performed immunofluorescence co-localization of IL33 staining with lineage markers and found high IL-33 expression in SeV-challenged
mice occurring exclusively in type II alveolar cells, with 97% of IL-33-positive cells
also positive for pro-SP-C (pro-surfactant protein C). We found no measurable IL-33
staining in Krt14-positive basal cells of the conducting airways (Figure 9B) or in
CD68-positive alveolar macrophages (Figure 9C) (N = 100 cells in 3 mice for each
lineage marker). This definitively proved that the predominant source of IL-33 during
SeV infection is the alveolar lung epithelium.
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Figure 9: SeV infection in mice leads to the production of IL-33 from mainly
type II alveolar epithelial cells. (A-C) Images of the lungs of mice challenged with
SeV and then killed 49 days later. (A) Fluorescence staining for pro‐surfactant
protein C (proSPC) to identify type II alveolar cells (green), IL‐33 (red), and DAPI to
identify nuclei (blue). Inset shows IL‐33 expression in a type II alveolar cell. (B)
Fluorescence staining for cytokeratin 14 (Krt14) to identify airway basal cells (white
arrowhead), IL‐33, and DAPI as in (A), shows no apparent expression of IL‐33 in
basal cells. (C) Fluorescence staining for CD68 to identify macrophages (yellow),
and IL‐33 and DAPI as in (A), shows no apparent expression of IL‐33 in
macrophages (scale bar for (A-C) = 200 μm, and for inset in (A) = 30 μm; n = 3
mice/antibody pair)
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5.3 Pam2-ODN treatment after viral clearance reduced eosinophils by reducing
IL-33 production in lung cells.
While it became clear that Pam2-ODN pretreatment reduced asthma features
by way of reducing the viral burden and IL-33 production in the lungs. This proved
the capacity of Pam2-ODN treatment in preventing the progression of SeV infections
to asthma-like disease. We now wanted to know whether Pam2-ODN treatment after
virus clearance from the lungs can reduce asthma-like disease on day 49, thus
acting as an immunomodulator. Therefore, we aerosolized mice with Pam2-ODN 20
days after SeV challenge (when virus is no longer detected in the mouse lungs –
Figures 1 and 2) and measured eosinophils as a measure for asthma features. We
found reduced eosinophilia on day 49 in mice treated with Pam2-ODN on day 20
after SeV challenge in comparison to untreated SeV challenged mice (Figure 10A).
There was no significant difference in BAL eosinophils between mice treated with
Pam2-ODN on day -1 or day +20 (Figure 10A). Therefore, Pam2-ODN treatment
certainly has an immunomodulatory capacity to reduce eosinophilia. We next
hypothesized if the reduction in eosinophilia is due to a reduction in IL-33 by Pam2ODN treatment on day +20. Therefore, we measured IL-33 protein levels from
homogenized lungs by ELISA and found that IL-33 is reduced on day 49 by Pam2ODN treatment on day +20 of SeV challenge. Like in the case of eosinophilia, there
was no significant difference in IL-33 levels from mice treated with Pam2-ODN on
day -1 or day +20 (Figure 10B). Therefore, these datasets provide evidence that
Pam2-ODN treatment after viral clearance can reduce asthma features such as
eosinophils and IL-33 production.
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Figure 10: Pam2-ODN treatment after viral clearance reduced eosinophils by
reducing IL-33 production in lung cells. (A) Eosinophils after differential Giemsa
staining of BAL cells on day 49 of SeV challenge with or without Pam2-ODN
treatment at day -1 or day +20. (B) IL-33 protein levels determined by ELISA on day
49 of SeV challenge with or without Pam2-ODN treatment on day -1 or day +20.
**p<0.01; ***p<0.005; One-way ANOVA with multiple comparisons.
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5.4 Summary and discussion
In the previous chapter, we found the major mechanism of Pam2-ODN
inducible resistance via reduction of pathogen burden, thereby enhancing the host
survival of respiratory infections. However, a major consequence of acute respiratory
viral infections is the development of the chronic asthma-like disease. Holtzman and
colleagues have demonstrated that an acute SeV infection in mice leads to the
production of IL-33 from the airway and type II epithelial cells [6, 9]. And, this IL-33
production is necessary for the development of asthma characterized by
eosinophilia, airway hyperreactivity, and mucus metaplasia [9]. Using the SeV
model, our lab has found that Pam2-ODN treatment can prevent the progression to
asthma-like disease by primarily reducing the viral burden. In this study, we found
further evidence that Pam2-ODN can prevent progression to asthma by additionally
reducing IL-33 production from lung epithelial cells at all times assessed (Figures 8,
9). The finding that IL-33 was predominantly produced by type II alveolar epithelial
cells because of SeV infection was important given that IL-33 was essential in the
development of SeV-induced chronic asthma. Holtzman’s group showed IL-33 to be
expressed in both airways and type II epithelial cells in mice upon SeV infection [9].
Interestingly, we found IL-33 expression only in type II alveolar epithelial cells and
none in airway basal cells [110]. Further, Holtzman’s group also showed IL-33 to be
expressed by airway basal cells in human COPD patients, which is not reproducible
in the mouse model of SeV induced asthma disease [9]. Our findings prompted us to
investigate whether there are additional benefits to Pam2-ODN treatment other than
the reduction in pathogen burden. Interestingly, we found reduced eosinophils on
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day 49 of SeV infection when mice were challenged with SeV and then treated with
Pam2-ODN after viral clearance (day +20) (Figure 10A).
Given our prior observations that Pam2-ODN inducible resistance is local, it
made sense to investigate the extent of epithelial IL-33 reduction in this approach of
late Pam2-ODN treatment after viral clearance. Indeed, we found reduced IL-33 on
day 49 of SeV infection, suggesting that Pam2-ODN treatment may possess
immunomodulatory functions that work by lowering epithelial IL-33. Further, this is
an important proof-of-principle finding that suggests therapeutic stimulation of lungs’
mucosal responses may redirect the lungs microenvironment into non-inflammatory
and protective response and/or induce tolerance against the impact of acute SeV-led
disease. One way to understand the mechanisms of epithelial IL-33 reduction by
Pam2-ODN treatment is by analyzing transcriptomic changes in the lung at the
single-cell level. Future investigations in the lab combining cellular, transcriptomic,
and epigenetic changes upon Pam2-ODN treatment are required to uncover the
immune gene activity in lung epithelial cells and may explain IL-33 regulation in lung
epithelial cells.
These studies may prove helpful in informing future therapeutics on unique
epithelial-driven mechanisms on reduction in organ injury and may help in defining
host resistance vs host tolerance functions of Pam2-ODN treatment.
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Chapter 6: Determine the viral-killing mechanisms of Pam2-ODN treatment in
lung epithelial cells
The following chapter is based on my publications, used with permission granted by
mBIO and American Thoracic Society. The data and figures presented in this
chapter are entirely my work.
Reprinted with permission of the American Thoracic Society.
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The American Journal of Respiratory Cell and Molecular Biology is an official journal
of the American Thoracic Society.
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Our findings from chapters 4 and 5 indicate that pretreatment of mice with
Pam2-ODN initiates anti-viral effects to enhance host survival, and therefore
prevents infected mice from developing asthma-like symptoms. As the antiviral
protection consistently correlated with reduced viral burden in vivo, (Figure 1 and 2)
and as the reduced virus burden likely contributes to the reduced CD8+ T cell levels
(Figure 4), we next sought to determine how Pam2-ODN-induced responses cause
antiviral effects. We investigated at what stage of viral entry into lung epithelial cells,
does Pam2-ODN mediate anti-viral effects. Viral entry into epithelial cells is via
attachment to receptors on lung epithelial cells, which mediates the virus entry into
the cells. Therefore, we investigated whether the anti-viral effect of Pam2-ODN
occurs before or after virus internalization to epithelial cells.
Further, our lab had previously investigated host survival of virus-infected cells
with or without Pam2-ODN pretreatment and found that Pam2-ODN treated virusinfected cells demonstrated enhanced survival. More interestingly, Pam2-ODN
treatment of cells alone displayed greater enhanced XTT conversion and
MitoTracker Red signals without any virus infection [107]. This led to the finding that
Pam2-ODN treatment-induced ROS that proved to be necessary for Pam2-ODN
mediated anti-viral protection [107]. Therefore, using the SeV model of viral
pneumonia, we also investigated whether Pam2-ODN induced ROS is also
necessary for anti-SeV protection in isolated lung epithelial cells and in mice.

6.1 Pam2-ODN treatment leads to extracellular inactivation of virus particles
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Assessing the effect of Pam2-ODN on SeV burden in immortalized mouse
epithelial cells (MLE-15) and primary mouse tracheal epithelial cells (mTEC), we
found that Pam2-ODN treatment reduced SeV burden at every time point measured,
reflecting the inducible antiviral capacity of isolated epithelial cells (Figure 11).
Further, we investigated whether the principal Pam2-ODN effect occurred before
(extracellular) or after (intracellular) virus internalization into their epithelial targets.
SeV inoculation was carried out at 4º C preventing SeV internalization while allowing
SeV attachment to epithelial cells. Using multiple methods to determine the effect of
Pam2-ODN on SeV attachment, we found no differences in the attachment of SeV to
lung epithelial targets (Figure 12A-D).
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Figure 11: Pam2-ODN pretreatment reduced virus burden in isolated lung
epithelial cells. SeV M gene expression assessed by qPCR at various time points
upon SeV inoculation with or without Pam2-ODN pretreatment in MLE-15 (A) or
mTCEs (B). *p<0.05, **p<0.01.
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Figure 12. Pam2-ODN inhibits SeV without altering attachment. (A) Flow
cytometry to measure virus attachment to epithelial cells 4 h after SeV challenge. (B)
Representative examples of immunofluorescence for virus attachment.
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Figure 12 continued. Pam2-ODN inhibits SeV without altering attachment. (C)
Percentage of SeV positive epithelial cells from (A). (D) Mean fluorescence intensity
of SeV-exposed epithelial cells 4 h after SeV challenge.

Even though similar numbers of virus particles were attached to epithelial cells,
when these attached virus particles were liberated from the epithelial cell targets,
virus particles from Pam2-ODN-treated epithelial cells were less able to
subsequently infect other naive epithelial cells (Figure 13A-C). As the number of
attached virus particles was the same, this difference in SeV burden in cells that
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received liberated virus particles from PBS vs Pam2-ODN treated cells indicated that
SeV is inactivated prior to epithelial internalization (Figure 13A-C).

Figure 13. Pam2-ODN inhibits SeV prior to epithelial internalization. (A)
Experimental outline showing viral attachment and prevention of virus internalization
by epithelial cells. SeV M gene expression in untreated MLE-15 cells (B) or primary
tracheal epithelial cells (C) challenged with the liberated virus (uninternalized virus
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particles) from cultures that had been pretreated with PBS or Pam2-ODN prior to
SeV infection 24 h after transfer of liberated virus to new cells. Data are
representative of five independent experiments. *p<0.05

6.2 Pam2-ODN-induced epithelial ROS protect against SeV infection and CD8+
T cell immunopathology
The anti-influenza response initiated by Pam2-ODN requires epithelial
generation of ROS from both NADPH-dependent dual oxidase and mitochondrial
sources [107]. Extending these findings to the SeV model in lung epithelial cells, an
NADPH oxidase inhibitor (GKT 137831) fully abrogated the Pam2-ODN-induced
anti-SeV response (Figure 14A). Similarly, treatment with a combination of FCCP
(an uncoupler of oxidative phosphorylation) and TTFA (a complex II inhibitor)
obviated the Pam2-ODN-induced anti-SeV response (Figure 14B) [107, 109] in
isolated lung epithelial cells.
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Figure 14: Pam2-ODN induced reactive oxygen species protects against SeV
virus infection in isolated lung epithelial cells. SeV burden in MLE-15 cells with
or without treatment with Pam2-ODN and/or NADPH inhibitors (A) or mitoROS
inhibitors (B). Data are representative of three independent experiments. **p<0.01,
*p<0.05
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Figure 15: Pam2-ODN induced reactive oxygen species protects against acute
SeV virus infections in mice. (A) Experimental outline.

Further, congruent with these in vitro studies, mice treated with FCCP and
TTFA before Pam2-ODN treatment and SeV challenge (Figure 15A) demonstrated
reduced survival (Figure 15B), increased SeV burden (Figure 15C). Since we had
earlier found that SeV induced immunopathology and mouse mortality was
associated with lung CD8+ T cells on day 10, we found that mtROS blockade in
Pam2-ODN treated, SeV challenged mice displayed enhanced lung CD8+ T cells on
day 10 (Figure 16). Further, it was found that Pam2-ODN induced epithelial
generation of mitochondrial ROS were required for inactivation of SeV before
epithelial entry (Figure 17).
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Figure 15 continued: Pam2-ODN induced reactive oxygen species protects
against acute SeV virus infections in mice. (B) Survival of SeV challenge in mice
treated with PBS or Pam2-ODN and/or mtROS inhibitors. (C) Lung SeV burden
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measured on day 5. n=13 mice/group in experiment (B). Data are representative of
three independent experiments. **p<0.01 compared to PBS, †p<0.05 compared to
Pam2-ODN-treated mice without ROS inhibition, *p<0.05 compared to PBS.

Figure 16. Pam2-ODN induced reactive oxygen species reduce SeV induced
CD8+ T cells. Lung CD8+ T cells assessed on day 10. Data are representative of
three independent experiments. *p<0.05, ns – not significant.
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Figure 17: Pam2-ODN induced ROS is essential for SeV inactivation prior to
epithelial internalization. SeV M gene expression in untreated MLE-15 cells
challenged with liberated virus from cells that had been pretreated with PBS or
Pam2-ODN burden and mitoROS inhibitors. ***p<0.0001; p<0.005
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6.3 Role of Type I IFN in Pam2-ODN mediated anti-viral effects
In addition to ROS mediated anti-viral protection by Pam2-ODN treatment, we
also investigated whether Pam2-ODN treatment-induced type I IFN as an anti-viral
mechanism. Prior studies from our lab have demonstrated that there was no
association of inducible resistance with type I IFN sensitive genes by microarray
analysis [103, 108]. This was evident in isolated lung epithelial cells and mouse lung
homogenates after Pam2-ODN treatment [71, 72, 103]. Hence, it was likely that type
I interferons were not involved in Pam2-ODN induced resistance against viral
pneumonia. However, these studies only demonstrated that Pam2-ODN treatment
alone did not lead to induction of type I IFN responsive genes, not whether Pam2ODN treatment alone and/or together with a viral challenge led to the induction of
type I IFNs. Therefore, it was hypothesized that type I IFNs are induced in lung
epithelial cells after Pam2-ODN pretreatment and subsequent viral challenge.

6.4 Pam2-ODN mediated anti-viral immunity is mediated in a Type I IFN
independent manner
When mouse tracheal epithelial cells (mTECs) were treated with Pam2-ODN
and PBS alone, at various times post-treatment, we found no induction of IFN-β
(Figure 18). As expected, PBS treated, virus challenged (Flu or SeV) mTECs
produced copious amounts of IFN-β congruent with prior reports on IFN induction
upon viral infection (Figure 18). These data suggest that while virus infection of
epithelial cells led to the production of IFN-β, Pam2-ODN pretreatment of virus
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challenged cells significantly decreased IFN-β probably due to reduced viral burden
associated with Pam2-ODN treatment. As congruent with prior microarray gene
expression data from our lab, Pam2-ODN treatment alone did not produce any IFN
at any time points assessed in lung epithelial cells [107].
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Figure 18: Pam2-ODN treatment alone or with viral challenge does not induce
type I IFN production. IFN-β levels from mouse tracheal epithelial cells treated with
Pam2-ODN or PBS 4 h prior to SeV (A) or Flu challenge (B). *p < 0.05 versus PBStreated samples; †p < 0.02 versus PBS-treated and virus-infected cells.
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Since Pam2-ODN treatment alone or with virus challenge did not produce
significant IFN-β in lung epithelial cells, we wanted to confirm that Pam2-ODN
mediates anti-viral immunity via type I IFN independent pathway. To assess the role
of IFN signaling in Pam2-ODN mediated anti-viral immunity, we used IFNAR-/- mice
that lack type I IFN signaling. While PBS treated, Flu challenged IFNAR-/- mice
displayed enhanced susceptibility to Flu challenge, Pam2-ODN pretreatment of
IFNAR-/- mice rescued these mice from mortality of Flu challenge (Figure 19A).
Further, the increased virus burden in IFNAR-/- mice was associated with increased
mortality of Flu infection (Figure 19A, B). However, Pam2-ODN treatment of IFNAR-/mice displayed significantly reduced virus burden and did not differ from the WT
mice further confirming that type I IFN signaling is not required for controlling virus
burden by Pam2-ODN (Figure 19B). These data were remarkably interesting
because not only were type I IFN not required for Pam2-ODN mediated protection,
but Pam2-ODN treatment rescues these mice from mortality of virus infections
despite the lack of IFN signaling.
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Figure 19: Pam2-ODN inducible anti-viral resistance is independent of type I
IFN signaling. (A) Viral burden assessed by Influenza NP gene expression from
mice treated with Pam2-ODN or PBS before influenza A challenge in IFNAR-/- or
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C57BL/6J mice. (B) Mouse survival of influenza A challenge in IFNAR-/- or C57BL/6J
mice pretreated with Pam-ODN or PBS.

6.5 Summary and discussion
These data revealed that mouse lung epithelial cells can be therapeutically
stimulated to induce robust antiviral responses reducing viral burden and this can, in
turn, enhance mouse survival during viral infections. Knowing that Pam2-ODNinducible resistance required ROS production to protect against influenza [107], we
studied the role of ROS in Pam2-ODN-mediated reduction in SeV burden and found
that ROS inhibition led to the loss of Pam2-ODN mediated anti-viral effects in
isolated lung epithelial cells (Figure 14). In vivo ROS inhibition not only led to
attenuation of Pam2-ODN’s anti-viral effect but allowed increased lung CD8+ T cell
numbers, implicating Pam2-ODN-induced ROS in preventing both identified
mechanisms of mouse mortality in SeV pneumonia (Figures 15, 16). ROS inhibition
led to the loss of Pam2-ODN-inducible in vitro inactivation of SeV prior to epithelial
internalization (Figure 17), demonstrating for the first time that epithelial ROS directly
contribute to virus inactivation. While our group has demonstrated inducible
resistance against multiple respiratory pathogens including viruses [73, 102, 103]
these studies demonstrate for the first time when in the virus lifecycle the anti-viral
effects begin (viz., prior to internalization), and substantiate the role of ROS in
protection against SeV (Figures 12, 13).
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The antiviral protection afforded by Pam2-ODN pretreatment did not require
type I IFN signaling, which was congruent with our prior microarray data that did not
show any IFN inducible genes (Figure 18, 19). Further, Pam2-ODN treatment
enhanced mouse survival of viral infections despite the lack of type I IFN signaling,
suggesting its applicability in IFN deficient populations (Figure 19). Importantly, this
finding also placed importance on novel type I IFN independent mechanisms such
as induction of epithelial ROS from mitochondrial as well as NADPH oxidase
sources. Production of ROS as a microbicidal mechanism has been widely reported
in phagocytic cells [89-93]. However, this mechanism has not been extensively
studied in non-phagocytic cells where it apparently acts predominantly extracellularly
rather than intracellularly as in phagocytes. These findings of viral inactivation by
epithelial ROS production reveal an essential component of inducible epithelial
resistance. Future investigations in the lab will include understanding the role of type
III IFNs and inflammasome activation as possible additional anti-viral mechanisms
utilized by Pam2-ODN treatment.
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Chapter 7: Discussion and Future Directions
In this thesis project, we have demonstrated that therapeutic stimulation of the
lung epithelium enhances mouse survival of acute SeV infections by reducing virus
burden and attenuating host immunopathology. Further, Pam2-ODN treatment
before or after viral clearance prevented the progression to SeV-induced chronic
asthma by reducing the viral burden and reducing IL-33 produced by lung epithelial
cells.
Our findings are potentially informative in the context of treating viral pneumonia

in human subjects, including those suffering from lung injury associated with SARSCoV-2 (Figure 20). Of note, the median period from SARS-CoV-2 exposure to
respiratory distress is 9 to 13 days, identical to the period from viral inoculation to
death from pneumonitis in this study of SeV pneumonia in mice [2]. Further, it was
recently reported that dexamethasone treatment confers a survival advantage to
COVID-19 requiring respiratory support and in those recruited after the first week of
their illness [121]. This suggests a stage of disease dominated by immunopathology,
rather than active viral replication, similar to our observation in the SeV model nine
days after viral challenge. It will be interesting to test the effects of dexamethasone
on CD8+ T cell activity and host mortality in the SeV model.

Host survival of acute infections is the goal when defining immunity against
infectious diseases. However, there are additional life-long host changes that can be
life-threatening long after the host survives the infection. One such example is where
respiratory viruses can induce molecular and structural changes in the lungs’
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microenvironment leading to chronic asthma [4-6]. Therefore, the outcome of any
interventional strategies against respiratory viral infections must not only be host
survival but also inducing host tolerance by limiting the health impact caused by
virus infections. In that regard, Pam2-ODN treatment of mice before viral challenge
seems to be a reasonable approach to prevent the progression of virus-induced
asthma. This approach relied heavily on host resistance of infection by limiting
pathogen burden. However, we also tested the efficacy of Pam2-ODN in mitigating
the SeV-induced asthma-like disease long after viral clearance from the lungs (thus
relying on non-viral killing mechanisms). Very interestingly, we found reduced
asthma-like features when mice were treated with Pam2-ODN 20 days after SeV
infection, revealing the immunomodulatory capacity of Pam2-ODN treatment. Since
lung epithelial IL-33 is essential for SeV-induced asthma, it was important to find the
extent of IL-33 reduction in late Pam2-ODN treatment. The reduction in lung
epithelial IL-33 in mice treated with Pam2-ODN on day +20 of SeV challenge (Figure
10), indicates that Pam2-ODN treatment perhaps directly limits the damage caused
by viral infections at the epithelial level. However, other possible immunomodulatory
mechanisms may play a role as well since we don’t fully understand the mechanism
of lung IL-33 production after an acute respiratory virus infection.

Several possible explanations for IL-33 reduction in our model may be inferred
from prior literature on IL-33. IL-33 has been traditionally identified as a nuclear
alarmin released because of cells underdoing necrosis during infections or other
assaults [6, 9, 79, 94, 101]. Virus-led host inflammation and injury may lead to
necrosis and as a result, IL-33 is released as a damage signal to initiate repair and
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proliferative mechanisms in the lungs. The mice that survive the SeV infection begin
to produce IL-33 from day 21 to 49 (Figure 8) (long after acute cell death events Figure 3), possibly for an indefinite time. Indeed, when mouse lungs undergo repair,
SeV-induced proliferation of lung epithelial cells and appearance of progenitor basal
stem cells was observed on day 14 (after viral clearance) [122]. These basal stem
cells continue to persist on day 49 of SeV infection and possibly long after that.
Further, these basal stem cells are normally present in young mice, not abundantly
found in adult mice, and function to restore homeostasis and give rise to type II
alveolar epithelial cells [6, 9, 113, 122]. And, our finding that type II epithelial cells
are the dominant source of IL-33 production during SeV infection might indicate that
Pam2-ODN treatment can reprogram the transcriptional machinery in these
epithelial basal stem cells to initiate a restorative epithelial cell fate that does not
lead to injurious IL-33 production. The reprograming may occur at a transcriptional
and/or epigenetic level where changes are persistent, long-lasting, and durable. It
remains to be seen however, how the lung epithelial compartment is changed at the
cellular and transcriptional level by Pam2-ODN treatment. Therefore, it can be
broadly hypothesized that Pam2-ODN treatment in addition to inducing broad antimicrobial responses in the lungs, may also induce a favorable transcriptional
program in the lung epithelium initiating reprogrammed cell repair and proliferation
pathway to restore homeostasis in the lungs (indicative of host tolerance).

Indeed, prior investigations on transcriptomic changes in mouse lungs and
isolated lung epithelial cells after Pam2-ODN revealed a flux of differentially
expressed genes (DEGs) that may play a role in inducing a broad anti-microbial
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resistance and/or disease tolerance upon a secondary assault [108]. If we combine
the lung transcriptomic changes with chromatin mapping analysis, we could
potentially find epigenetically poised genes that may have unrealized potential for
disease tolerance or protective immune activity. The concept of realized and
unrealized epigenetic potential was recently reported in detail in structural cells
where low expression of immune active genes coupled with higher open chromatin
marks suggested unrealized epigenetic potential which turned on after a systemic
viral infection [123]. Similarly, in our model of Pam2-ODN pretreatment, we could
hypothesize that the lung epithelial genes with an immune or protective function that
are lowly expressed in homeostatic conditions may be epigenetically poised for
higher expression upon subsequent infection. These immune function genes may be
epigenetically pre-programmed for a rapid response to a variety of immunological
challenges such as virus infection in the form of higher cytokine/chemokine
production. It will be interesting to also study the effect of Pam2-ODN-induced
epithelial ROS in inducing transcriptomic and epigenetic changes in the lungs for the
rapid response upon a secondary assault. These are several lines of future
investigation in the laboratory to better understand the broad protection afforded by
Pam2-ODN treatment.

The discovery that skin epithelial basal stem cells can remember acute
inflammation and insults to induce persistent and durable protection against
secondary insults is remarkable supporting evidence to our anti-asthma
investigations by Pam2-ODN treatment [124]. Therefore, another related mechanism
could be that Pam2-ODN induced lung epithelial responses remain persistent and
89

durable for a long time due to epigenetic training and memory. The support for this
hypothesis also comes from multiple studies of trained innate immunity in the
hematopoietic system [24, 25, 27]. One could hypothesize that Pam2-ODN
treatment before or after viral challenge can induce persisting memory in the lung
epithelium of prior insults (virus challenge or Pam2-ODN treatment) that can lead to
faster resolution and durability against secondary insults. Comprehensive studies to
explore these hypotheses require the use of single-cell sequencing and screening of
epigenetic and transcriptional changes in the lungs’ epithelium after Pam2-ODN
treatment. Further, structural cells such as endothelium and fibroblasts need to be
investigated for their involvement in long-term memory since substantial evidence
indicating their role in the regulation of systemic leukocyte immune response has
now been gathered [123].

Another possible area of investigation is at the IL-33 and group 2 innate
lymphoid cells (ILC2) axis. Epithelial IL-33 produced can activate lung dendritic cells
and/or ILC2 to initiate a maladaptive type 2 immune response in the airways. The
latter series of events may also be an important area of investigation to understand
how targeting lung epithelial cells may redirect or reprogram the host leukocyte
population to be less inflammatory or maladaptive, especially by the control of lung
epithelial cytokines such as IL-33. Indeed, our lab has found that Pam2-ODN
treatment also reduces eosinophilic inflammation and airway hyperreactivity in nonpathogenic models of asthma (unpublished data). Therefore, there is clear evidence
of immunomodulation that may or may not use the same anti-microbial strategies
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used to induce host resistance. Defining resistance and tolerance mechanisms by
targeting the lungs' epithelial responses will be an area of future investigation.

Taken together, our findings provide mechanistic insights into the antiviral
responses generated by the lung epithelium, prevention of host immunopathology,
and asthma-like disease that may inform future therapeutics to target
immunomodulation as a means to improve the outcomes of respiratory infections in
vulnerable population.
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Figure 20: Strategies to improve the outcome of respiratory virus infections.
Two ways to enhance survival of respiratory virus infections – 1) By early stimulation
of innate immunity which leads to epithelial ROS inactivating virus particles prior to
internalization into epithelial targets, thus reducing viral replication and lung damage
and in turn enhancing host survival. 2) By the suppression of host immune response
after virus-induced inflammation in the lungs is established, thereby decreasing lung
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damage associated with host CD8+ T cells and enhancing host survival. Figure
created with BioRender.com.
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